

**Title: Association of Obesity with COVID-19 Severity and Mortality: A Systemic Review and Meta-Regression**

**Authors:** Romil Singh\*<sup>1</sup>, Sawai Singh Rathore\*<sup>2</sup>, Hira Khan<sup>3</sup>, Smruti Karale<sup>4</sup>, Abhishek Bhurwal<sup>5</sup>, Aysun Tekin<sup>1</sup>, Nirpeksh Jain<sup>6</sup>, Ishita Mehra<sup>7</sup>, Sohini Anand<sup>8</sup>, Sanjana Reddy<sup>9</sup>, Guneet Singh Sidhu<sup>10</sup>, Anastasios Panagopoulos<sup>11</sup>, Vishwanath Pattan<sup>12</sup>, Rahul Kashyap<sup>1</sup>, Vikas Bansal<sup>13</sup>

<sup>1</sup>Department of Anesthesiology and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota, USA

<sup>2</sup>Medical Student, Dr. Sampurnanand Medical College, Jodhpur, Rajasthan, India

<sup>3</sup>Department of Internal Medicine, Islamic International Medical College, Rawalpindi, Pakistan

<sup>4</sup>Department of Internal Medicine, Government Medical College-Kolhapur, Kolhapur, Maharashtra, India

<sup>5</sup>Department of Gastroenterology and Hepatology, Rutgers Robert Wood Johnson School of Medicine, New Brunswick, New Jersey, USA

<sup>6</sup>Department of Emergency Medicine, Marshfield Clinic, Marshfield, Wisconsin, USA

<sup>7</sup>Department of Internal Medicine, North Alabama Medical Center, Florence, Alabama, USA

<sup>8</sup>Medical Graduate, Patliputra Medical College and Hospital, Dhanbad, Jharkhand, India

<sup>9</sup>Medical Student, Gandhi Medical College, Secunderabad, India

<sup>10</sup>Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA

<sup>11</sup>Department of Cardiology, University of Nebraska Medical Center, Omaha, NE, USA

<sup>12</sup>Division of Endocrinology, Wyoming Medical center, Casper, WY, USA

<sup>13</sup>Department of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota, USA

**Corresponding Author:**

Vishwanath Pattan, MD

Division of Endocrinology

Wyoming Medical Center

419 S Washington St Suite 201

Casper, WY-82601

Email: vpattan@wyoingmedicalcenter.org

Phone: (307) 577-2592

**Word count:** 3237

**Tables:** 2

**Figures:** 8, multi panel

**Conflict of Interest:** None of the co-authors have anything to declare.

**Financial Support:** There is no financial disclosure related to this study.

**Author Contribution:** \*Authors 1(RS) and 2(SSR) contributed equally in defining the study outline and manuscript writing. Data review and collection were done by AT, GSS, HK, NJ, RS, SK, AP, and SSR; statistical analysis was done by AB, SK, and VB; risk of bias was done by AT, SA and SSR. Study design, Distribution of Articles for critical review done by IM, VP, RK, and VB. Final approval received by all authors. RS, SSR, VB and VP is the guarantor of the paper, taking responsibility for the integrity of the work as a whole,

**from inception to published article. All authors contributed to the article and approved the submitted version.**

## **Abstract**

**Objective:** To estimate the association of obesity with severity (defined as use of invasive mechanical ventilation or intensive care unit admission) and all-cause mortality in coronavirus disease 2019 (COVID-19) patients.

**Patients and Methods:** A systematic search was conducted from inception of COVID-19 pandemic through January 31st, 2021 for full-length articles focusing on the association of increased BMI/ Obesity and outcome in COVID-19 patients with help of various databases including Medline (PubMed), Embase, Science Web, and Cochrane Central Controlled Trials Registry. Preprint servers such as BioRxiv, MedRxiv, ChemRxiv, and SSRN were also scanned. Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines were used for study selection and data extraction. The severity in hospitalized COVID-19 patients, such as requirement of invasive mechanical ventilation and intensive care unit admission with high BMI/ Obesity was the chief outcome. While all-cause mortality in COVID-19 hospitalized patients with high BMI/ Obesity was the secondary outcome.

**Results:** A total of 576,784 patients from 100 studies were included in this meta-analysis. Being obese was associated with increased risk of severe disease (RR=1.46, 95% CI 1.34-1.60,  $p<0.001$ ,  $I^2 = 92\%$ ). Similarly, high mortality was observed in obese patients with COVID-19 disease (RR=1.12, 95% CI 1.06-1.19,  $p<0.001$ ,  $I^2 = 88\%$ ). In a multivariate meta-regression on severity outcome, the covariate of female gender, pulmonary disease, diabetes, older age, cardiovascular diseases, and hypertension was found to be significant and explained  $R^2= 50\%$  of the between-study heterogeneity for severity. Similarly, for mortality outcome, covariate of female gender, proportion of pulmonary disease, diabetes, hypertension, and cardiovascular

diseases were significant, these covariates collectively explained  $R^2=53\%$  of the between-study variability for mortality.

**Conclusions:**

Our findings suggest that obesity is significantly associated with increased severity and higher mortality among COVID-19 patients. Therefore, the inclusion of obesity or its surrogate body mass index in prognostic scores and streamlining the management strategy and treatment guidelines to account for the impact of obesity in patient care management is recommended.

1 **Introduction:**

2 The entire world is enduring the effects of the global coronavirus disease 2019 (COVID-19)  
3 pandemic since its inception in December 2019 when pneumonia of unknown origin was  
4 diagnosed in Hubei province, Wuhan, China<sup>1,2</sup>. It was later in January 2020 that the novel  
5 coronavirus strand was isolated and subsequently named severe acute respiratory syndrome  
6 coronavirus 2 (SARS-CoV-2) in February 2020<sup>3,4</sup>. As of now, till 4<sup>th</sup> April, 2021, the Covid-19  
7 pandemic has affected 131,129,824 individuals and has led to 2,850,174 global deaths<sup>5</sup>. Despite  
8 the fact that many treatments have been proposed to combat COVID-19, there is currently no  
9 uniformly successful therapy<sup>6-12</sup>. Although it is a widespread disease affecting multiple systems,  
10 obesity has been identified as one of the major comorbid factors in patients suffering from  
11 COVID-19<sup>13-22</sup>.

12 Overweight (BMI 25 kg/m<sup>2</sup>-29.9 kg/m<sup>2</sup>) and obesity (BMI 30 kg/m<sup>2</sup> or more) are a major public  
13 health problem, especially during the COVID-19 pandemic, because of their association with  
14 increased morbidity and mortality<sup>23,24</sup>. Berrington de Gonzalez et al. (2010) studied the  
15 association of overweight and obesity on overall mortality in 1.46 million white adults over a  
16 median follow-up period of 10 years. They found approximately linear relationship in the hazard  
17 ratios for the BMI. The hazard ratio for every 5-unit increment of BMI was 1.31 in the BMI  
18 range of 25 kg/m<sup>2</sup> to 49.9 kg/m<sup>2</sup>.<sup>25</sup> According to the 2017-2018 National Health and Nutrition  
19 Examination Survey (NHANES), about 42.5% of U.S. adults aged 20 or more are obese and  
20 approximately 9% have class 3 obesity or severe obesity (BMI 40 kg/m<sup>2</sup> or more)<sup>26</sup>. The  
21 prevalence of obesity has been increasing rapidly in the last decade.

22 According to WHO, the prevalence of obesity has nearly tripled in the last four decades  
23 amounting to 13% of the entire world's adult population<sup>27</sup>. This exponential rise in the obesity  
24 rates in the midst of the pandemic is a cause for concern. The interplay between obesity and  
25 diabetes mellitus, cardiovascular disease, stroke, dyslipidemia, influenza has been established for  
26 a long time. The presence of these comorbid determinants has been related to increased  
27 predisposition and severity of COVID-19<sup>28-31</sup>. Many studies have reported increased rates of  
28 hospitalization, mechanical ventilation, and mortality in patients with higher BMI<sup>32-36</sup>.

29 To mitigate the impact of heightened morbidity and mortality associated with COVID-19  
30 infection in patients with obesity, it is vital to be cognizant of the implications of increased BMI  
31 and its dynamic interaction with other comorbid components. Hence, we evaluated obesity as a  
32 paramount risk factor for mortality and severity in COVID-19 infection, independent of potential  
33 confounders via systematic review and meta-regression.

## 34 **Methods:**

### 35 **Search method and Strategy**

36 For documentation, we adopted the Preferred Systematic Analyses and Meta-Analysis Reporting  
37 Items recommendations<sup>37</sup>. A systematic search was conducted from COVID-19 databases from  
38 the pandemic inception through January 31<sup>st</sup>, 2021 for full-length articles focusing on the  
39 association of increased BMI/ Obesity in COVID-19 using a pre-specified data extraction  
40 protocol including bibliographic information (year of publication, first author), study  
41 information (country, sample size), patient characteristics (age, baseline comorbidities, gender),  
42 treatment information and outcome data. The search strategy consisted of keywords "SARS-  
43 CoV-2", "COVID-19", "CORONAVIRUS", "OBESITY", "BMI", "OVERWEIGHT" across the

44 COVID-19 database which included articles from Medline (PubMed), Embase, Science Web,  
45 and Cochrane Central Controlled Trials Registry. Studies were included from all over the world,  
46 there were no language barriers. Other literature sources such as the BioRxiv (preprints),  
47 MedRxiv (preprints), ChemRxiv (preprints), and SSRN (preprints) were searched as well. After  
48 following a thorough search, full-length articles meeting the inclusion criteria were evaluated. In  
49 an attempt to discover further eligible studies, we manually searched the reference lists of the  
50 included studies, and previously published meta-analysis, systematic review, and the relevant  
51 literature. We also scanned the clinicaltrials.gov registry for completed, as well as in-progress  
52 randomized controlled trials (RCTs).

### 53 **Eligibility Criteria:**

54 The inclusion criteria for the systematic review are as follows:

- 55 1. Studies reporting outcomes such as severity or mortality events, at least one functional  
56 endpoint of COVID-19 hospitalized patients with increased BMI.
- 57 2. Full text, peer-reviewed articles (Case-studies and case series, randomized controlled trials)  
58 were included.

### 59 **Study selection**

60 The authors (HK and SSR) downloaded all articles from electronic search to EndNote X9<sup>38</sup> and  
61 duplicates were eliminated. Based on the preset eligibility criteria, each study was reviewed by  
62 two reviewers (AT, GSS, HK, NJ, RS, SK and SSR) independently, and disagreements were  
63 discussed amongst all author-reviewers and resolved via a consensus. The cases included obese  
64 Covid-19 positive hospitalized patients and the controls included the non-obese Covid-19

65 positive hospitalized patients. Unadjusted and adjusted impact measurements were also extracted  
66 where appropriate. From each study, various details including first author name, study type,  
67 hospitalized total covid-19 positive patients, the definition of COVID-19 severity, definition of  
68 obesity, total obese & non-obese COVID-19 positive patients, patients with high severity and  
69 mortality, median age, gender (female sex proportion), hypertension proportion, pulmonary  
70 disease proportion, cardiovascular disease proportion, diabetes proportion, dyslipidemia  
71 proportion, liver disease proportion were mentioned in a tabulated format in excel sheet. These  
72 details are exhibited in Table 1. The included data was checked for accuracy by all authors.  
73 Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines were used.  
74 Figure 1.

## 75 **Outcomes**

76 All-cause severity in hospitalized COVID-19 patients with high BMI/ Obesity was the primary  
77 outcome. The severity rate was evaluated in comparison to the control group (non-obese  
78 COVID-19 hospitalized patients). While all-cause mortality in COVID-19 hospitalized patients  
79 with high BMI/ obesity was the secondary outcome.

## 80 **Statistical analysis**

81 The meta-analysis specifically included case-control and cohort studies comparing the effects of  
82 high BMI/Obesity in COVID-19 hospitalized patients comparing them to the non-obese COVID-  
83 19 hospitalized patients. All outcomes were analyzed using the Mantel-Haenszel method for  
84 dichotomous data to estimate pooled risk ratio (RR) utilizing the Review Manager (RevMan)-  
85 Version 5.4, The Cochrane Collaboration, 2020. Meta-analysis was performed first for studies  
86 reporting severity of patients in both groups followed by that for studies reporting severity of



87 disease assuming independence of results for studies that reported both. Due to anticipated  
88 heterogeneity, summary statistics were calculated using a random-effects model. This model  
89 accounts for variability between studies as well as within studies. Statistical heterogeneity was  
90 assessed using Q value and  $I^2$  statistics.

91 To explore differences between studies that might be expected to influence the effect size, we  
92 performed random effects (maximum likelihood method) univariate and multivariate meta-  
93 regression analyses. The potential sources of variability hypothesized were the gender of the  
94 study sample, the proportion of subjects with diabetes, pulmonary disease, cardiovascular  
95 disease, and hypertension. Covariates were selected for further modeling if they significantly  
96 ( $P < 0.05$ ) modified the association between mortality or severity in the COVID-19 hospitalized  
97 patients with high BMI/Obesity. Two models were created, one for severity and the other for  
98 mortality of disease as outcomes. Subsequently, preselected covariates were included in a  
99 manual backward and stepwise multiple meta-regression analysis with  $P = 0.05$  as a cutoff point  
100 for removal.  $P < 0.05$ . ( $P < 0.10$  for heterogeneity) was considered statistically significant. All  
101 meta-analysis and meta-regression tests were 2-tailed. The meta-regression was done with the  
102 Comprehensive Meta-Analysis software package (Biostat, Englewood, NJ, USA)<sup>14</sup><sup>39</sup>.

103 We conducted sensitivity analysis with BMI categories (BMI  $< 18$  kg/m<sup>2</sup>, BMI 18 kg/m<sup>2</sup>-25 kg/m<sup>2</sup>,  
104 BMI 25 kg/m<sup>2</sup>-29.9 kg/m<sup>2</sup>, BMI  $> 30$  kg/m<sup>2</sup>, and BMI  $> 40$  kg/m<sup>2</sup>) to decrease inherent selection  
105 bias in observational studies<sup>40</sup>.

## 106 **Risk of Bias**

107 Risk of Bias assessment- The Newcastle-Ottawa (NOS) scale<sup>12</sup> was used for measuring the risk  
108 of bias in case-control studies and cohort studies. The following classes were rated per study:

109 low bias risk (9 points), moderate bias risk (5-7 points), and high bias risk (0-4 items. For a  
110 cross-sectional study, we used the modified version of NOS, assigning the study in the following  
111 groups: Low risk of bias (8-10), moderate risk (5-7), high risk of bias (0-4) )<sup>41</sup>. Three reviewers  
112 (AT, SA, and SSR) evaluated the likelihood of bias independently, and any conflict was resolved  
113 by consensus (Table 2A and 2B).

## 114 **Results**

### 115 **Study characteristics of included studies**

116 For the primary endpoint, severity, a total of 100 studies, consisting of 576,784 patients were  
117 included in the meta-analysis. The median age for included patients was 61.4 (55.3-65) with  
118 average 42.9% females (Table 1). Of the comorbidities considered, 29.4% were diabetics, 37.9%  
119 had heart diseases overall. Similarly, for the primary endpoint, i.e. disease severity, a total of  
120 seventy reports were included in the meta-analysis <sup>32,42-110</sup>. These had a combined sample size of  
121 292,165 with 40,272 patients reaching the endpoint of high disease severity (Table 1). Similarly,  
122 a total of 51 studies were included for meta-analysis for the secondary outcome i.e.  
123 mortality<sup>42,45,46,48-52,55,63,66,75,79,80,82,85,88,89,92,101,109,111-140</sup>. These had a combined sample size of  
124 380,130 with 118,351 patients reaching the endpoint of mortality.

125 **Meta-analysis for severity outcome:** Findings from the meta-analysis showed that being obese  
126 was correlated with increased severity of COVID 19 infections in comparison to non-obese  
127 patients (RR=1.46, 95% CI 1.34-1.60, p<0.001). Heterogeneity was high with  $I^2 = 92\%$  (Figure  
128 2).

129 **Meta-analysis for mortality outcome:** Meta-analysis findings showed that obesity was  
130 associated with increased risk of mortality from COVID 19 infections in comparison to non-

131 obese patient population (RR=1.12, 95% CI 1.06-1.19, p<0.001). Heterogeneity was high with I<sup>2</sup>  
132 = 88% (Figure 3).

133 **Multivariate meta-regression model for severity outcome:** Multivariate meta-regression was  
134 performed to explain variations in the association between COVID-19 severity and obesity. We  
135 found female gender, pulmonary disease, diabetes, age, cardiovascular diseases, and  
136 hypertension covariates to be significant and this explained R<sup>2</sup>= 50% of the between-study  
137 heterogeneity in severity. The proportion of hypertension did not significantly affect the  
138 between-study variations and were therefore not included in the final equation. Figure 4 shows  
139 the resulting equation and individual covariate effect graphs.

140 **Multivariate meta-regression model for mortality outcome:** Multivariate meta-regression  
141 performed to explain variations in the association between mortality and obesity revealed that  
142 female gender, proportion of pulmonary disease, diabetes, hypertension, and cardiovascular  
143 diseases to be significant together. Overall, these covariates together explained R<sup>2</sup>=53% of the  
144 between-study heterogeneity in mortality. Figure 5 shows the resulting equation and individual  
145 covariate effect graphs.

146 **Publication Bias:** Visual inspection of the standard error plots for the severity analysis also  
147 (Figure 7A) suggests symmetry without an underrepresentation of studies of any precision.  
148 However, in Egger's regression test the null hypothesis of no small study effects was rejected at  
149 p<0.05 (estimated bias coefficient = -0.13 ± 0.42SE).

150 Similarly, visual inspection of the standard error plots for the mortality analysis (Figure 7B)  
151 suggests symmetry without an underrepresentation of studies of any precision. Corroborating

152 inspection findings, Egger's regression test, the null hypothesis of no small study effects, was  
153 rejected at  $p < 0.05$  (estimated bias coefficient =  $-0.17 \pm 0.42SE$ ).

154 **Sensitivity analysis:** We did not find any statistical significance for risk of mortality as well as  
155 the risk for severity with COVID-19 when analyzed by BMI categories. However, we observed  
156 that underweight status ( $BMI < 18 \text{ kg/m}^2$ ) is associated with increased risk of mortality in COVID-  
157 19 (OR 1.52, 95% CI 1.19-1.94,  $p < 0.001$ ;  $I^2 = 0\%$ ) but not statistical significant to severity of  
158 COVID-19 (OR 1.10, 95% CI 0.81-1.48,  $p = 0.54$ ;  $I^2 = 0\%$ ) as compared to normal BMI category of  
159  $18 \text{ kg/m}^2$ - $25 \text{ kg/m}^2$ . We also did not observe any statistically significant changes while comparing  
160 BMI category  $25 \text{ kg/m}^2$  to  $29.9 \text{ kg/m}^2$  with respect to others in terms of mortality and severity of  
161 COVID-19 (Figure 6A-H).

## 162 **Discussion**

163 In this large meta-analysis with 100 studies, we found that obesity has a strong association with  
164 increased mortality & severity of COVID-19 infection. In addition, our meta-regression analysis  
165 suggests that obesity significantly increases the severity and mortality in COVID-19 patients.  
166 Using a random effects model, we found that obese patients showed higher odds for mortality  
167 and severity i.e. ICU admissions or mechanical ventilation. Our results suggest that obese  
168 individuals are 1.5 times more likely to experience severe outcomes and 1.12 times more likely  
169 to die when compared to non-obese individuals with COVID-19 disease. Our meta-regression  
170 severity model suggested that 50% of the heterogeneity could be explained by age, gender,  
171 diabetes, hypertension, pulmonary and cardiovascular diseases. The mortality meta-regression  
172 model suggested that 53% of the heterogeneity could be accounted for by gender, diabetes,

173 hypertension, pulmonary and cardiovascular diseases. Through these regression models, we were  
174 able to address major amount of heterogeneity seen in our meta-analysis.

175 In the existing literature, we found four meta-analysis (studies n=6, 17, 40, 76)<sup>141-144</sup> that  
176 explored the association of obesity and worse outcomes in COVID-19 and found a similar  
177 association. On the contrary, one study refuted the possibility of this association. Owing to their  
178 small sample population (Studies n=2), it is likely that they were underpowered to tease out the  
179 true difference or association<sup>145</sup>. With a much larger sample size (n=100) our study provides a  
180 more robust evidence to establish this association.

181 Five meta-regression studies have evaluated the direct relationship between obesity and COVID-  
182 19 over the last year. Yang et al (studies n=41) concluded that, in COVID-19 patients, obesity is  
183 associated with increased mortality, increased rates of hospitalization, ICU admissions and the  
184 need for mechanical ventilation. However, they found no confounding factors causing  
185 heterogeneity in regards to hospitalization, ICU admission, and in-hospital mortality of COVID-  
186 19 patients<sup>146</sup>. In another such study, Mesas et al (studies n=60) described that obesity was linked  
187 to increased mortality only in studies with fewer chronic or critical patients and reported mean  
188 age of patients as the most important source of heterogeneity, followed by sex and health  
189 condition<sup>147</sup>. Soereto et al (studies n=16) reported that patients with higher BMI were at  
190 increased risk of developing 'poor outcomes' - defined as mortality, ICU admission, ARDS  
191 incidence, severe COVID-19, need for mechanical ventilation and hospitalization. In their meta  
192 regression, the heterogeneity in poor outcomes was explained by age, type 2 diabetes mellitus,  
193 hypertension, and gender<sup>148</sup>. Du et al and Chu et al (studies n=16 and 22) found that the  
194 association between obesity and COVID-19 severity and that with mortality was significantly  
195 influenced by age, but not with gender or other co morbidities<sup>149,150</sup>. Our meta-regression

196 identified the likely confounders to be age, gender, and co-morbidities such as diabetes,  
197 hypertension, pulmonary and cardiovascular diseases. Through this model, we were able to  
198 explain high heterogeneity with highest number of confounders, which other meta regression in  
199 the recent literature were not able to reach and define<sup>146-150</sup>. Thus, we were able to establish a  
200 strong association that obesity plays a remarkable role in worsening these outcomes in patients  
201 with COVID-19 infection. In the sensitivity analyses, we were only able to find statistically  
202 significant results for increased mortality in BMI<18 kg/m<sup>2</sup> as compared to BMI 18 kg/m<sup>2</sup>-25  
203 kg/m<sup>2</sup>, however, such significance was not noted in any other BMI categories with severity and  
204 mortality in COVID-19. This could be due to BMI being a very crude estimate of adiposity, may  
205 not be sensitive enough to tease out the real difference. Visceral adiposity would probably be a  
206 more reliable estimate to study these differences. However, in their study, Anderson et al. found  
207 that patients with obesity have a greater chance of intubation or mortality, with people with class  
208 3 obesity having the greatest risk compared to overweight patients<sup>45</sup>.

209 Obesity is known to be associated with many adverse comorbid conditions<sup>151</sup> including  
210 hypertension, atherogenic dyslipidemia, cardiovascular disease, insulin resistance or type 2  
211 diabetes, altered cortisol metabolism, etc<sup>152</sup>. Obesity is associated with overexpression of ACE2  
212 receptors and higher ACE2 receptors may aid infection and serve as viral reservoir<sup>153</sup> Moreover,  
213 obesity is known to be associated with endothelial dysfunction<sup>154</sup>, the key pathogenic event in  
214 COVID-19 infection leading to mortality and morbidity<sup>155,156</sup>. Obesity or increased adiposity  
215 plays a key role in endothelial dysfunction by activating several cascade of pathological events  
216 namely- activation of renin-angiotensin system<sup>157</sup>, activation of procoagulant/hypercoagulation  
217 pathway<sup>158</sup>, activation of proinflammatory mediators<sup>159</sup>, insulin resistance<sup>160</sup>, oxidative stress

218 <sup>161</sup>, platelet dysfunction <sup>162</sup> and immune dysregulation <sup>163</sup>. These events are summarized in  
219 Figure 8.

220 In the study by Danzinger et al. obesity was found to be associated with increased incidence of  
221 acute kidney injury and increase in short- and long-term mortality<sup>164</sup>. Various meta-analyses  
222 were conducted to evaluate the association of obesity with mortality and severity of critically ill  
223 patients. The results were not universal, despite a wide variety of observations. In a total of  
224 62,045 critically ill patients, Akinnusi et al compared the ICU mortality between obese and non-  
225 obese patients and found no dissimilarities<sup>165</sup>. Hogue et al. (n=22) conducted a meta-analysis of  
226 88,051 patients and found that obesity did not impact ICU mortality<sup>166</sup>. However, Oliveros and  
227 Villamor et al. found that ICU mortality was increased only in underweight patients and reduced  
228 in overweight and obese patients<sup>167</sup>. In another study Zhao et al. observed that having a high  
229 BMI is related to longer duration on mechanical ventilation but lower mortality<sup>168</sup>. Therefore, it  
230 is unclear how obesity affects clinical outcomes in critically ill patients and more prospective  
231 studies are required to study the association between obesity and adverse outcomes in critical  
232 care.

233 The prime strength of this study is the large sample size. With an exhaustive search strategy, we  
234 compiled 100 studies conducted globally. We also added the most recent studies to our meta-  
235 analysis and meta-regression model including the studies that reported contradictory information.  
236 It enabled us to arrive at a more definitive conclusion about the risk associations. To define the  
237 heterogeneity in the meta-analysis, we also conducted a meta-regression analysis. For  
238 moderators, we used the most probable confounders based on the available evidence. This  
239 enabled us to delineate the impact of obesity as an independent risk factor for mortality and  
240 severity in COVID-19. However, our study is also subject to few limitations. We included five

241 studies from preprint databases<sup>71,76,83,96,101</sup> that may not be comparable to peer-reviewed articles  
242 in terms of their quality of methodology. However, in view of the time-sensitive nature of this  
243 pandemic, benefit of early dissemination of critical information and its inclusion in various  
244 analyses outweighs the risk from minor methodological flaws. Second factor was the  
245 heterogeneity in the studies in terms of the study design and methodology, patient sample and  
246 treatment received. There was a lack of uniformity in the type of outcomes evaluated for severity  
247 and their definitions in different studies. For the same reason, it was not possible to deduce the  
248 effect of obesity on the individual outcomes- ICU admission and mechanical ventilation. Third  
249 limitation is that the analysis was done with hospitalized patients only; hence we cannot  
250 generalize our results for patients seen in the outpatient clinic or treated at home. Analyzing  
251 outpatient data as well may help us to get the complete picture of the impact of obesity on the  
252 overall COVID-19 outcomes. Fourth limitation is that our analysis did not compare the outcomes  
253 with respect to visceral obesity and only BMI was used. However, it was beyond the scope of  
254 this analysis because of the lack of those details in most of the included studies. We suggest that  
255 prospective studies should obtain and report this information about their sample population.  
256 Lastly, it is possible that some confounders which could have otherwise accounted for the  
257 residual heterogeneity were not evaluated in the meta-regression analysis due to limited  
258 information.

259 **Conclusion:** In summary, our findings suggest that obesity significantly increases the risk of  
260 severity and mortality in hospitalized COVID-19 patients. Therefore, the inclusion of obesity or  
261 surrogate body mass index or visceral obesity in prognostic scores and streamlining the  
262 management strategy and treatment guidelines to account for the impact of obesity would be  
263 vital to improve patient outcomes in hospitalized COVID-19 patients. Our finding also serves as



264 a call for the scientific community to further delve into its pathophysiology and identify potential  
265 pharmacological targets, since COVID-19 is an ever-evolving disease. Finally, this information  
266 must be disseminated to the general public to intensify the primary prevention of obesity.

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282 **References:**

283 1. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with  
284 COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*. 2020;395(10229):1054-1062.

285 2. Shah A, Kashyap R, Tosh P, Sampathkumar P, O'Horo JC. Guide to Understanding the 2019 Novel  
286 Coronavirus. *Mayo Clin Proc*. 2020;95(4):646-652.

287 3. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern.  
288 *Lancet*. 2020;395(10223):470-473.

289 4. Organization WH. Naming the coronavirus disease (COVID-19) and the virus that causes it.  
290 World Health Organization. [https://www.who.int/emergencies/diseases/novel-coronavirus-  
291 2019/technical-guidance/naming-the-coronavirus-disease-\(covid-2019\)-and-the-virus-that-  
292 causes-it](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it). Published 2020. Accessed March 17, 2021.

293 5. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time.  
294 *Lancet Infect Dis*. 2020;20(5):533-534.

295 6. Bansal V, Mahapure K, Bhurwal A, et al. Mortality Benefit of Remdesivir in COVID-19: A  
296 Systematic Review and Meta-analysis. *Frontiers in Medicine*. 2020;7:1124.

297 7. Jain R, Javeri Y, Nasa P, et al. Consensus Statement for Pharmacological Management of  
298 Coronavirus Disease 2019 (COVID-19): A Pragmatic Approach. *Asploro Journal of Biomedical and  
299 Clinical Case Reports*. 2020;3(3):241.

300 8. R Singh LS, I Mehra, R Kashyap, S Surani. Novel and Controversial Therapies in COVID-19. *The  
301 Open Respiratory Medicine Journal*. 2020;14.

302 9. Bansal V, Mahapure K, Mehra I, et al. Mortality Benefit of Convalescent Plasma in COVID-19: A  
303 Systematic Review and Meta-analysis. *Frontiers in Medicine*. 2021;8:250.

304 10. Singh R, Rathore SS, Khan H, et al. Mortality and Severity in COVID-19 Patients on ACEIs &  
305 ARBs - A Meta-Regression Analysis. *medRxiv*. 2021:2021.2003.2014.21253557.

306 11. Singh R, Rathore SS, Khan H, et al. Mortality and Severity in COVID-19 Patients on ACEIs & ARBs-  
307 A Meta-Regression Analysis. *medRxiv*. 2021.

308 12. Karale S, Bansal V, Makadia J, et al. A Meta-analysis of Mortality, Need for ICU admission, Use of  
309 Mechanical Ventilation and Adverse Effects with Ivermectin Use in COVID-19 Patients. *medRxiv*.  
310 2021:2021.2004.2030.21256415.

311 13. Prevention CfDca. People with Certain Medical Conditions. CDC.  
312 [https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-  
313 conditions.html](https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html). Published 2021. Updated March 15, 2021. Accessed March 17, 2021.

314 14. Rathore SS, Rojas GA, Sondhi M, et al. Myocarditis associated with Covid-19 disease: a  
315 systematic review of published Case reports and Case series. *Authorea Preprints*. 2021.

316 15. Sheraton M, Deo N, Kashyap R, Surani S. A Review of Neurological Complications of COVID-19.  
317 *Cureus*. 2020;12(5):e8192.

318 16. Singh R, Kashyap R, Hutton A, Sharma M, Surani S. A Review of Cardiac Complications in  
319 Coronavirus Disease 2019. *Cureus*. 2020;12(5):e8034.

320 17. Shah K, Bedi S, Onyeaka H, Singh R, Chaudhari G. The Role of Psychological First Aid to Support  
321 Public Mental Health in the COVID-19 Pandemic. *Cureus*. 2020;12(6):e8821.

322 18. Shah K, Mann S, Singh R, Bangar R, Kulkarni R. Impact of COVID-19 on the Mental Health of  
323 Children and Adolescents. *Cureus*. 2020;12(8):e10051.

324 19. Menon T, Sharma R, Kataria S, et al. The Association of Acute Kidney Injury With Disease  
325 Severity and Mortality in COVID-19: A Systematic Review and Meta-Analysis. *Cureus*. 2021;13(3).

326 20. Singh R, Shiza ST, Saadat R, Dawe M, Rehman U. Association of Guillain-Barre Syndrome With  
327 COVID-19: A Case Report and Literature Review. *Cureus*. 2021;13(3).

- 328 21. Menon T, Sharma R, Earthineni G, et al. Association of Gastrointestinal System With Severity and  
329 Mortality of COVID-19: A Systematic Review and Meta-Analysis. *Cureus*. 2021;13(2):e13317.
- 330 22. Menon T, Gandhi SAQ, Tariq W, et al. Impact of Chronic Kidney Disease on Severity and  
331 Mortality in COVID-19 Patients: A Systematic Review and Meta-analysis. *Cureus*.  
332 2021;13(4):e14279.
- 333 23. Whitlock G, Lewington S, Sherliker P, et al. Body-mass index and cause-specific mortality in 900  
334 000 adults: collaborative analyses of 57 prospective studies. *Lancet*. 2009;373(9669):1083-1096.
- 335 24. Goyal P, Ringel JB, Rajan M, et al. Obesity and COVID-19 in New York City: A Retrospective  
336 Cohort Study. *Annals of Internal Medicine*. 2020;173(10):855-858.
- 337 25. Berrington de Gonzalez A, Hartge P, Cerhan JR, et al. Body-mass index and mortality among 1.46  
338 million white adults. *N Engl J Med*. 2010;363(23):2211-2219.
- 339 26. Fryar CD, Carroll MD, Afful J. *Prevalence of Overweight, Obesity, and Severe Obesity Among  
340 Adults Aged 20 and Over: United States, 1960–1962 Through 2017–2018*. Centers for Disease  
341 Control and Prevention; December 2020 2020.
- 342 27. Organization WH. Obesity and overweight. WHO. [https://www.who.int/news-room/fact-  
343 sheets/detail/obesity-and-overweight](https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight). Published 2020. Accessed March 17, 2021.
- 344 28. Barnes AS. The epidemic of obesity and diabetes: trends and treatments. *Tex Heart Inst J*.  
345 2011;38(2):142-144.
- 346 29. Klop B, Elte JW, Cabezas MC. Dyslipidemia in obesity: mechanisms and potential targets.  
347 *Nutrients*. 2013;5(4):1218-1240.
- 348 30. Fifi JT, Mocco J. COVID-19 related stroke in young individuals. *Lancet Neurol*. 2020;19(9):713-  
349 715.
- 350 31. Jain S, Chaves SS. Obesity and Influenza. *Clinical Infectious Diseases*. 2011;53(5):422-424.
- 351 32. Kalligeros M, Shehadeh F, Mylona EK, et al. Association of Obesity with Disease Severity Among  
352 Patients with Coronavirus Disease 2019. *Obesity*. 2020;28(7):1200-1204.
- 353 33. Prevention CfDca. Obesity, Race/Ethnicity, and COVID-19. CDC.  
354 <https://www.cdc.gov/obesity/data/obesity-and-covid-19.html>. Published 2020. Accessed March  
355 17, 2021.
- 356 34. Hendren NS, Lemos JAd, Ayers C, et al. Association of Body Mass Index and Age With Morbidity  
357 and Mortality in Patients Hospitalized With COVID-19. *Circulation*. 2021;143(2):135-144.
- 358 35. Domecq JP, Lal A, Sheldrick CR, et al. Outcomes of Patients With Coronavirus Disease 2019  
359 Receiving Organ Support Therapies: The International Viral Infection and Respiratory Illness  
360 Universal Study Registry. *Critical Care Medicine*. 9000;Online First.
- 361 36. Walkey AJ, Kumar VK, Harhay MO, et al. The Viral Infection and Respiratory Illness Universal  
362 Study (VIRUS): An International Registry of Coronavirus 2019-Related Critical Illness. *Critical Care  
363 Explorations*. 2020;2(4).
- 364 37. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews  
365 and meta-analyses of studies that evaluate healthcare interventions: explanation and  
366 elaboration. *BMJ*. 2009;339:b2700.
- 367 38. Hupe M. EndNote X9. *Journal of Electronic Resources in Medical Libraries*. 2019;16(3-4):117-119.
- 368 39. Borenstein M, Hedges L, Higgins J, Rothstein H. *Comprehensive Meta-Analysis Version 3*. Biostat,  
369 Englewood, NJ 2013. <https://www.meta-analysis.com/index.php?cart=BBFA4702757>. Published  
370 2013. Updated 03/11/2021. Accessed 03/11/2021.
- 371 40. Higgins JPT, Thomas J, Chandler J, et al. *Cochrane handbook for systematic reviews of  
372 interventions*. John Wiley & Sons; 2019.
- 373 41. Wells GA SB, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale  
374 (NOS) for assessing the quality of nonrandomised studies in meta-analyses.

- 375 [http://www.ohri.ca/programs/clinical\\_epidemiology/oxford.asp](http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp). Published 2009. Accessed  
376 August 20, 2020.
- 377 42. Al Heialy S, Hachim MY, Hachim IY, et al. Combination of obesity and co-morbidities leads to  
378 unfavorable outcomes in COVID-19 patients. *Saudi J Biol Sci*. 2021;28(2):1445-1450.
- 379 43. Al-Sabah S, Al-Haddad M, Al-Youha S, Jamal M, Almazeedi S. COVID-19: Impact of Obesity and  
380 Diabetes in Disease Severity. *Clin Obes*. 2020;10(6):e12414.
- 381 44. Alkhatib AL, Kreniske J, Zifodya JS, et al. BMI is Associated with Coronavirus Disease 2019  
382 Intensive Care Unit Admission in African Americans. *Obesity*. 2020;28(10):1798-1801.
- 383 45. Anderson MR, Geleris J, Anderson DR, et al. Body Mass Index and Risk for Intubation or Death in  
384 SARS-CoV-2 Infection : A Retrospective Cohort Study. *Ann Intern Med*. 2020;173(10):782-790.
- 385 46. Arjun S, Farraj K, Yeroushalmi K, et al. EVALUATING OBESITY PARADOX IN COVID 19: INSIGHTS  
386 FROM A SAFETY-NET HOSPITAL IN NEW YORK. *Chest*. 2020;158(4, Supplement):A302.
- 387 47. Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in Critically Ill Patients in the Seattle  
388 Region — Case Series. *New England Journal of Medicine*. 2020;382(21):2012-2022.
- 389 48. Biscarini S, Colaneri M, Ludovisi S, et al. The obesity paradox: Analysis from the SMAteo COvid-  
390 19 REgistry (SMACORE) cohort. *Nutrition, Metabolism and Cardiovascular Diseases*.  
391 2020;30(11):1920-1925.
- 392 49. Burrell AJ, Pellegrini B, Salimi F, et al. Outcomes for patients with COVID-19 admitted to  
393 Australian intensive care units during the first four months of the pandemic. *Medical Journal of  
394 Australia*. 2021;214(1):23-30.
- 395 50. Busetto L, Bettini S, Fabris R, et al. Obesity and COVID-19: An Italian Snapshot. *Obesity*.  
396 2020;28(9):1600-1605.
- 397 51. Cai Q, Chen F, Wang T, et al. Obesity and COVID-19 Severity in a Designated Hospital in  
398 Shenzhen, China. *Diabetes Care*. 2020;43(7):1392-1398.
- 399 52. Cariou B, Hadjadj S, Wargny M, et al. Phenotypic characteristics and prognosis of inpatients with  
400 COVID-19 and diabetes: the CORONADO study. *Diabetologia*. 2020;63(8):1500-1515.
- 401 53. Caussy C, Wallet F, Laville M, Disse E. Obesity is Associated with Severe Forms of COVID-19.  
402 *Obesity*. 2020;28(7):1175-1175.
- 403 54. Chao JY, Derespina KR, Herold BC, et al. Clinical Characteristics and Outcomes of Hospitalized  
404 and Critically Ill Children and Adolescents with Coronavirus Disease 2019 at a Tertiary Care  
405 Medical Center in New York City. *J Pediatr*. 2020;223:14-19.e12.
- 406 55. Czernichow S, Beeker N, Rives-Lange C, et al. Obesity Doubles Mortality in Patients Hospitalized  
407 for Severe Acute Respiratory Syndrome Coronavirus 2 in Paris Hospitals, France: A Cohort Study  
408 on 5,795 Patients. *Obesity*. 2020;28(12):2282-2289.
- 409 56. Dreher M, Kersten A, Bickenbach J, et al. The Characteristics of 50 Hospitalized COVID-19  
410 Patients With and Without ARDS. *Dtsch Arztebl Int*. 2020;117(16):271-278.
- 411 57. Ebinger JE, Achamallah N, Ji H, et al. Pre-existing traits associated with Covid-19 illness severity.  
412 *PLoS One*. 2020;15(7):e0236240.
- 413 58. Feuth T, Saaresranta T, Karlsson A, et al. Is sleep apnea a risk factor for Covid-19? findings from a  
414 retrospective cohort study. *Sleep Medicine and Disorders: International Journal*. 2020;4(3).
- 415 59. Gao F, Zheng KI, Wang X-B, et al. Obesity Is a Risk Factor for Greater COVID-19 Severity. *Diabetes  
416 Care*. 2020;43(7):e72-e74.
- 417 60. Gerotziafas GT, Sergentanis TN, Voirit G, et al. Derivation and Validation of a Predictive Score  
418 for Disease Worsening in Patients with COVID-19. *Thromb Haemost*. 2020;120(12):1680-1690.
- 419 61. Goyal P, Choi JJ, Pinheiro LC, et al. Clinical Characteristics of Covid-19 in New York City. *New  
420 England Journal of Medicine*. 2020;382(24):2372-2374.

- 421 62. Guner R, Hasanoglu I, Kayaaslan B, et al. COVID-19 experience of the major pandemic response  
422 center in the capital: results of the pandemic's first month in Turkey. *Turk J Med Sci.*  
423 2020;50(8):1801-1809.
- 424 63. Hajifathalian K, Kumar S, Newberry C, et al. Obesity is Associated with Worse Outcomes in  
425 COVID-19: Analysis of Early Data from New York City. *Obesity.* 2020;28(9):1606-1612.
- 426 64. Hur K, Price CPE, Gray EL, et al. Factors Associated With Intubation and Prolonged Intubation in  
427 Hospitalized Patients With COVID-19. *Otolaryngology–Head and Neck Surgery.* 2020;163(1):170-  
428 178.
- 429 65. Iaccarino G, Grassi G, Borghi C, et al. Gender differences in predictors of intensive care units  
430 admission among COVID-19 patients: The results of the SARS-RAS study of the Italian Society of  
431 Hypertension. *PLoS One.* 2020;15(10):e0237297.
- 432 66. Ioannou GN, Locke E, Green P, et al. Risk Factors for Hospitalization, Mechanical Ventilation, or  
433 Death Among 10 131 US Veterans With SARS-CoV-2 Infection. *JAMA Netw Open.*  
434 2020;3(9):e2022310.
- 435 67. Kaeuffer C, Le Hyaric C, Fabacher T, et al. Clinical characteristics and risk factors associated with  
436 severe COVID-19: prospective analysis of 1,045 hospitalised cases in North-Eastern France,  
437 March 2020. *Euro Surveill.* 2020;25(48).
- 438 68. Lighter J, Phillips M, Hochman S, et al. Obesity in Patients Younger Than 60 Years Is a Risk Factor  
439 for COVID-19 Hospital Admission. *Clinical Infectious Diseases.* 2020;71(15):896-897.
- 440 69. Lodigiani C, Iapichino G, Carenzo L, et al. Venous and arterial thromboembolic complications in  
441 COVID-19 patients admitted to an academic hospital in Milan, Italy. *Thromb Res.* 2020;191:9-14.
- 442 70. Mejía-Vilet JM, Córdova-Sánchez BM, Fernández-Camargo DA, Méndez-Pérez RA, Morales  
443 Buenrostro LE, Hernández-Gilsoul T. A risk score to predict admission to the intensive care unit  
444 in patients with Covid-19: the ABC-GOALS score. *Salud Publica Mex.*  
445 2020:2020.2005.2012.20099416.
- 446 71. Mendy A, Apewokin S, Wells AA, Morrow AL. Factors Associated with Hospitalization and  
447 Disease Severity in a Racially and Ethnically Diverse Population of COVID-19 Patients. *medRxiv.*  
448 2020:2020.2006.2025.20137323.
- 449 72. Monteiro AC, Suri R, Emeruwa IO, et al. Obesity and smoking as risk factors for invasive  
450 mechanical ventilation in COVID-19: A retrospective, observational cohort study. *PLoS One.*  
451 2020;15(12):e0238552.
- 452 73. Mughal MS, Kaur IP, Jaffery AR, et al. COVID-19 patients in a tertiary US hospital: Assessment of  
453 clinical course and predictors of the disease severity. *Respir Med.* 2020;172:106130.
- 454 74. Nachege JB, Ishoso DK, Otokoye JO, et al. Clinical Characteristics and Outcomes of Patients  
455 Hospitalized for COVID-19 in Africa: Early Insights from the Democratic Republic of the Congo.  
456 *The American Journal of Tropical Medicine and Hygiene.* 2020;103(6):2419-2428.
- 457 75. Nakeshbandi M, Maini R, Daniel P, et al. The impact of obesity on COVID-19 complications: a  
458 retrospective cohort study. *Int J Obes (Lond).* 2020;44(9):1832-1837.
- 459 76. Newton S, Zollinger B, Freeman J, et al. Factors associated with clinical severity in Emergency  
460 Department patients presenting with symptomatic SARS-CoV-2 infection. *medRxiv.*  
461 2020:2020.2012.2008.20246017.
- 462 77. Ortiz-Brizuela E, Villanueva-Reza M, Gonzalez-Lara MF, et al. Clinical and Epidemiological  
463 Characteristics of Patients Diagnosed with Covid-19 in a Tertiary Care Center in Mexico City: A  
464 Prospective Cohort Study. *Rev Invest Clin.* 2020;72(3):165-177.
- 465 78. Palaiodimos L, Kokkinidis DG, Li W, et al. Severe obesity, increasing age and male sex are  
466 independently associated with worse in-hospital outcomes, and higher in-hospital mortality, in a  
467 cohort of patients with COVID-19 in the Bronx, New York. *Metabolism.* 2020;108:154262.

- 468 79. Pepe M, Maroun-Eid C, Romero R, et al. Clinical presentation, therapeutic approach, and  
469 outcome of young patients admitted for COVID-19, with respect to the elderly counterpart.  
470 *Clinical and Experimental Medicine*. 2021.
- 471 80. Petersen A, Bressemer K, Albrecht J, et al. The role of visceral adiposity in the severity of COVID-  
472 19: Highlights from a unicenter cross-sectional pilot study in Germany. *Metabolism*.  
473 2020;110:154317.
- 474 81. Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness  
475 among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study.  
476 *BMJ*. 2020;369:m1966.
- 477 82. Pettit NN, MacKenzie EL, Ridgway JP, et al. Obesity is Associated with Increased Risk for  
478 Mortality Among Hospitalized Patients with COVID-19. *Obesity (Silver Spring)*. 2020;28(10):1806-  
479 1810.
- 480 83. Philipose Z, Smati N, Wong CSJ, Aspey K, Mendall M. Obesity, old age, and frailty are the true  
481 risk factors for COVID-19 mortality and not chronic disease or ethnicity. *MedRxiv*. 2020.
- 482 84. Pongpirul WA, Wiboonchutikul S, Charoenpong L, et al. Clinical course and potential predictive  
483 factors for pneumonia of adult patients with Coronavirus Disease 2019 (COVID-19): A  
484 retrospective observational analysis of 193 confirmed cases in Thailand. *PLOS Neglected Tropical*  
485 *Diseases*. 2020;14(10):e0008806.
- 486 85. Ramlall V, Thangaraj PM, Meydan C, et al. Immune complement and coagulation dysfunction in  
487 adverse outcomes of SARS-CoV-2 infection. *Nat Med*. 2020;26(10):1609-1615.
- 488 86. Rao X, Wu C, Wang S, et al. The importance of overweight in COVID-19: A retrospective analysis  
489 in a single center of Wuhan, China. *Medicine*. 2020;99(43).
- 490 87. Reilev M, Kristensen KB, Pottegård A, et al. Characteristics and predictors of hospitalization and  
491 death in the first 11 122 cases with a positive RT-PCR test for SARS-CoV-2 in Denmark: a  
492 nationwide cohort. *International Journal of Epidemiology*. 2020;49(5):1468-1481.
- 493 88. Rodríguez-Molinero A, Gálvez-Barrón C, Miñarro A, et al. Association between COVID-19  
494 prognosis and disease presentation, comorbidities and chronic treatment of hospitalized  
495 patients. *PLoS One*. 2020;15(10):e0239571.
- 496 89. Rottoli M, Bernante P, Belvedere A, et al. How important is obesity as a risk factor for  
497 respiratory failure, intensive care admission and death in hospitalised COVID-19 patients?  
498 Results from a single Italian centre. *Eur J Endocrinol*. 2020;183(4):389-397.
- 499 90. Shekhar R, Upadhyay S, Sheikh A, Atencio J, Kapuria D. Early experience with COVID-19 patients  
500 at academic hospital in Southwestern United States. *Infect Dis (Lond)*. 2020;52(8):596-599.
- 501 91. Simonnet A, Chetboun M, Poissy J, et al. High Prevalence of Obesity in Severe Acute Respiratory  
502 Syndrome Coronavirus-2 (SARS-CoV-2) Requiring Invasive Mechanical Ventilation. *Obesity*.  
503 2020;28(7):1195-1199.
- 504 92. Steinberg E, Wright E, Kushner B. In Young Adults with COVID-19, Obesity Is Associated with  
505 Adverse Outcomes. *West J Emerg Med*. 2020;21(4):752-755.
- 506 93. Suleyman G, Fadel RA, Malette KM, et al. Clinical Characteristics and Morbidity Associated With  
507 Coronavirus Disease 2019 in a Series of Patients in Metropolitan Detroit. *JAMA Netw Open*.  
508 2020;3(6):e2012270.
- 509 94. Tonetti T, Grasselli G, Zanella A, et al. Use of critical care resources during the first 2 weeks  
510 (February 24–March 8, 2020) of the Covid-19 outbreak in Italy. *Annals of Intensive Care*.  
511 2020;10(1):133.
- 512 95. Urra JM, Cabrera CM, Porrás L, Ródenas I. Selective CD8 cell reduction by SARS-CoV-2 is  
513 associated with a worse prognosis and systemic inflammation in COVID-19 patients. *Clin*  
514 *Immunol*. 2020;217:108486.

- 515 96. Vaquero-Roncero LM, Sánchez-Barrado E, Escobar-Macias D, et al. C-Reactive protein and SOFA  
516 score as early predictors of critical care requirement in patients with COVID-19 pneumonia in  
517 Spain. *medRxiv*. 2020:2020.2005.2022.20110429.
- 518 97. Wang R, Xie L, Du P, Fan H, Song M. Clinical characteristics of 96 hospitalized patients with  
519 coronavirus disease 2019. *Chinese Journal of Respiratory and Critical Care Medicine*.  
520 2020;19(2):144-147.
- 521 98. Zheng KI, Gao F, Wang XB, et al. Letter to the Editor: Obesity as a risk factor for greater severity  
522 of COVID-19 in patients with metabolic associated fatty liver disease. *Metabolism*.  
523 2020;108:154244.
- 524 99. Gregoriano C, Koch D, Haubitz S, et al. Characteristics, predictors and outcomes among 99  
525 patients hospitalised with COVID-19 in a tertiary care centre in Switzerland: an observational  
526 analysis. *Swiss Med Wkly*. 2020;150:w20316.
- 527 100. Di Fusco M, Shea KM, Lin J, et al. Health outcomes and economic burden of hospitalized COVID-  
528 19 patients in the United States. *J Med Econ*. 2021;24(1):308-317.
- 529 101. Carrillo G, Méndez-Domínguez N, Santos-Zaldivar KD, et al. Clinical course and severity outcome  
530 indicators among COVID-19 hospitalized patients in relation to comorbidities distribution:  
531 Mexican cohort. *medRxiv*. 2020:2020.2007.2031.20165480.
- 532 102. Hu L, Chen S, Fu Y, et al. Risk Factors Associated With Clinical Outcomes in 323 Coronavirus  
533 Disease 2019 (COVID-19) Hospitalized Patients in Wuhan, China. *Clinical Infectious Diseases*.  
534 2020;71(16):2089-2098.
- 535 103. Frank RC, Mendez SR, Stevenson EK, Guseh JS, Chung M, Silverman MG. Obesity and the Risk of  
536 Intubation or Death in Patients With Coronavirus Disease 2019. *Critical Care Medicine*.  
537 2020;48(11).
- 538 104. Wang J, Zhu L, Liu L, et al. Overweight and Obesity are Risk Factors of Severe Illness in Patients  
539 with COVID-19. *Obesity*. 2020;28(11):2049-2055.
- 540 105. Ong SWX, Young BE, Leo Y-S, Lye DC. Association of Higher Body Mass Index With Severe  
541 Coronavirus Disease 2019 (COVID-19) in Younger Patients. *Clinical Infectious Diseases*.  
542 2020;71(16):2300-2302.
- 543 106. Xie J, Zu Y, Alkhatib A, et al. Metabolic Syndrome and COVID-19 Mortality Among Adult Black  
544 Patients in New Orleans. *Diabetes Care*. 2021;44(1):188-193.
- 545 107. Argenziano MG, Bruce SL, Slater CL, et al. Characterization and clinical course of 1000 patients  
546 with coronavirus disease 2019 in New York: retrospective case series. *Bmj*. 2020;369:m1996.
- 547 108. Hsu HE, Ashe EM, Silverstein M, et al. Race/Ethnicity, Underlying Medical Conditions,  
548 Homelessness, and Hospitalization Status of Adult Patients with COVID-19 at an Urban Safety-  
549 Net Medical Center — Boston, Massachusetts, 2020. Centers for Disease Control and  
550 Prevention. Morbidity and Mortality Weekly Report (MMWR) Web site.  
551 [https://www.cdc.gov/mmwr/volumes/69/wr/mm6927a3.htm?s\\_cid=mm6927a3\\_w](https://www.cdc.gov/mmwr/volumes/69/wr/mm6927a3.htm?s_cid=mm6927a3_w). Published  
552 2020. Updated July 10, 2020. Accessed March 17, 2021.
- 553 109. Min W, Fang Y, Xinxin Z, et al. Clinical characteristics and outcomes of patients with new  
554 coronavirus pneumonia with different body mass indexes. *Chinese Journal of Endocrinology and  
555 Metabolism*. 2020;36.
- 556 110. Motaib I, Zbiri S, Elamari S, Dini N, Chadli A, El Kettani C. Obesity and Disease Severity Among  
557 Patients With COVID-19. *Cureus*. 2021;13(2):e13165.
- 558 111. Chand S, Kapoor S, Orsi D, et al. COVID-19-Associated Critical Illness—Report of the First 300  
559 Patients Admitted to Intensive Care Units at a New York City Medical Center. *Journal of Intensive  
560 Care Medicine*. 2020;35(10):963-970.
- 561 112. Ciceri F, Castagna A, Rovere-Querini P, et al. Early predictors of clinical outcomes of COVID-19  
562 outbreak in Milan, Italy. *Clin Immunol*. 2020;217:108509.

563 113. Cravedi P, Mothi SS, Azzi Y, et al. COVID-19 and kidney transplantation: Results from the TANGO  
564 International Transplant Consortium. *Am J Transplant.* 2020;20(11):3140-3148.

565 114. de Andrade CLT, de Aguiar Pereira CC, Martins M, Lima SML, Portela MC. COVID-19  
566 hospitalizations in Brazil's Unified Health System (SUS). *PLoS One.* 2020;15(12):e0243126.

567 115. Bellan M, Patti G, Hayden E, et al. Fatality rate and predictors of mortality in an Italian cohort of  
568 hospitalized COVID-19 patients. *Sci Rep.* 2020;10(1):20731.

569 116. Rossi AP, Gottin L, Donadello K, et al. Obesity as a risk factor for unfavourable outcomes in  
570 critically ill patients affected by Covid 19. *Nutr Metab Cardiovasc Dis.* 2021;31(3):762-768.

571 117. Carrillo-Vega MF, Salinas-Escudero G, García-Peña C, Gutiérrez-Robledo LM, Parra-Rodríguez L.  
572 Early estimation of the risk factors for hospitalization and mortality by COVID-19 in Mexico. *PLoS*  
573 *One.* 2020;15(9):e0238905.

574 118. Cedano J, Fabian Corona E, Gonzalez-Lara M, et al. Characteristics and outcomes of patients  
575 with COVID-19 in an intensive care unit of a community hospital; retrospective cohort study. *J*  
576 *Community Hosp Intern Med Perspect.* 2021;11(1):27-32.

577 119. Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with  
578 covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational  
579 cohort study. *Bmj.* 2020;369:m1985.

580 120. de Souza FSH, Hojo-Souza NS, de Oliveira Batista BD, da Silva CM, Guidoni DL. On the analysis of  
581 mortality risk factors for hospitalized COVID-19 patients: A data-driven study using the major  
582 Brazilian database. *PLoS One.* 2021;16(3):e0248580.

583 121. Giacomelli A, Ridolfo AL, Milazzo L, et al. 30-day mortality in patients hospitalized with COVID-19  
584 during the first wave of the Italian epidemic: A prospective cohort study. *Pharmacol Res.*  
585 2020;158:104931.

586 122. Giorgi Rossi P, Marino M, Formisano D, et al. Characteristics and outcomes of a cohort of COVID-  
587 19 patients in the Province of Reggio Emilia, Italy. *PloS one.* 2020;15(8):e0238281.  
588 doi:10.1371/journal.pone.0238281. Accessed 2020.

589 123. Halasz G, Leoni ML, Villani GQ, Nolli M, Villani M. Obesity, overweight and survival in critically ill  
590 patients with SARS-CoV-2 pneumonia: is there an obesity paradox? Preliminary results from  
591 Italy. *European Journal of Preventive Cardiology.* 2020.

592 124. Kates OS, Haydel BM, Florman SS, et al. Coronavirus Disease 2019 in Solid Organ Transplant: A  
593 Multicenter Cohort Study. *Clinical Infectious Diseases.* 2020.

594 125. Klang E, Kassim G, Soffer S, Freeman R, Levin MA, Reich DL. Severe Obesity as an Independent  
595 Risk Factor for COVID-19 Mortality in Hospitalized Patients Younger than 50. *Obesity.*  
596 2020;28(9):1595-1599.

597 126. Murillo-Zamora E, Hernandez-Suarez CM. Survival in adult inpatients with COVID-19. *Public*  
598 *Health.* 2021;190:1-3.

599 127. Olivas-Martínez A, Cárdenas-Fragoso JL, Jiménez JV, et al. In-hospital mortality from severe  
600 COVID-19 in a tertiary care center in Mexico City; causes of death, risk factors and the impact of  
601 hospital saturation. *PLOS ONE.* 2021;16(2):e0245772.

602 128. Parker A, Koegelenberg CFN, Moolla MS, et al. High HIV prevalence in an early cohort of hospital  
603 admissions with COVID-19 in Cape Town, South Africa. *S Afr Med J.* 2020;110(10):982-987.

604 129. Parra-Bracamonte GM, Lopez-Villalobos N, Parra-Bracamonte FE. Clinical characteristics and risk  
605 factors for mortality of patients with COVID-19 in a large data set from Mexico. *Ann Epidemiol.*  
606 2020;52:93-98.e92.

607 130. Rodríguez A, Moreno G, Gómez J, et al. Severe infection due to the SARS-CoV-2 coronavirus:  
608 Experience of a tertiary hospital with COVID-19 patients during the 2020 pandemic. *Med*  
609 *Intensiva.* 2020;44(9):525-533.



- 610 131. Salacup G, Lo KB, Gul F, et al. Characteristics and clinical outcomes of COVID-19 patients in an  
611 underserved-inner city population: A single tertiary center cohort. *J Med Virol.* 2021;93(1):416-  
612 423.
- 613 132. Shah P, Owens J, Franklin J, et al. Demographics, comorbidities and outcomes in hospitalized  
614 Covid-19 patients in rural southwest Georgia. *Annals of Medicine.* 2020;52(7):354-360.
- 615 133. Di Castelnuovo A, Bonaccio M, Costanzo S, et al. Common cardiovascular risk factors and in-  
616 hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based  
617 findings from the multicentre Italian CORIST Study. *Nutr Metab Cardiovasc Dis.*  
618 2020;30(11):1899-1913.
- 619 134. Favà A, Cucchiari D, Montero N, et al. Clinical characteristics and risk factors for severe COVID-  
620 19 in hospitalized kidney transplant recipients: A multicentric cohort study. *American Journal of*  
621 *Transplantation.* 2020;20(11):3030-3041.
- 622 135. Kalyanaraman Marcello R, Dolle J, Grami S, et al. Characteristics and outcomes of COVID-19  
623 patients in New York City's public hospital system. *PLOS ONE.* 2020;15(12):e0243027.
- 624 136. Soares RCM, Mattos LR, Raposo LM. Risk Factors for Hospitalization and Mortality due to COVID-  
625 19 in Espírito Santo State, Brazil. *Am J Trop Med Hyg.* 2020;103(3):1184-1190.
- 626 137. Mikami T, Miyashita H, Yamada T, et al. Risk Factors for Mortality in Patients with COVID-19 in  
627 New York City. *J Gen Intern Med.* 2021;36(1):17-26.
- 628 138. Yudong P, Kai M, Liang L, et al. Clinical characteristics and outcome of 112 patients with  
629 cardiovascular disease infected with novel coronavirus pneumonia. *Chinese Journal of*  
630 *Cardiovascular Diseases.* 2020;48(6):450-455.
- 631 139. Halvatsiotis P, Kotanidou A, Tzannis K, et al. Demographic and clinical features of critically ill  
632 patients with COVID-19 in Greece: The burden of diabetes and obesity. *Diabetes Res Clin Pract.*  
633 2020;166:108331.
- 634 140. Borobia AM, Carcas AJ, Arnalich F, et al. A Cohort of Patients with COVID-19 in a Major Teaching  
635 Hospital in Europe. *J Clin Med.* 2020;9(6).
- 636 141. Földi M, Farkas N, Kiss S, et al. Visceral Adiposity Elevates the Risk of Critical Condition in COVID-  
637 19: A Systematic Review and Meta-Analysis. *Obesity (Silver Spring).* 2021;29(3):521-528.
- 638 142. Poly TN, Islam MM, Yang HC, et al. Obesity and Mortality Among Patients Diagnosed With  
639 COVID-19: A Systematic Review and Meta-Analysis. *Frontiers in Medicine.* 2021;8(28):620044.
- 640 143. Aghili SMM, Ebrahimpur M, Arjmand B, et al. Obesity in COVID-19 era, implications for  
641 mechanisms, comorbidities, and prognosis: a review and meta-analysis. *Int J Obes (Lond).*  
642 2021:1-19.
- 643 144. Booth A, Reed AB, Ponzo S, et al. Population risk factors for severe disease and mortality in  
644 COVID-19: A global systematic review and meta-analysis. *PLoS One.* 2021;16(3):e0247461.
- 645 145. Ng WH, Tipih T, Makoah NA, et al. Comorbidities in SARS-CoV-2 Patients: a Systematic Review  
646 and Meta-Analysis. *mBio.* 2021;12(1).
- 647 146. Yang J, Tian C, Chen Y, Zhu C, Chi H, Li J. Obesity aggravates COVID-19: An updated systematic  
648 review and meta-analysis. *J Med Virol.* 2020.
- 649 147. Mesas AE, Cavero-Redondo I, Álvarez-Bueno C, et al. Predictors of in-hospital COVID-19  
650 mortality: A comprehensive systematic review and meta-analysis exploring differences by age,  
651 sex and health conditions. *PLoS One.* 2020;15(11):e0241742.
- 652 148. Soeroto AY, Soetedjo NN, Purwiga A, et al. Effect of increased BMI and obesity on the outcome  
653 of COVID-19 adult patients: A systematic review and meta-analysis. *Diabetes Metab Syndr.*  
654 2020;14(6):1897-1904.
- 655 149. Du Y, Lv Y, Zha W, Zhou N, Hong X. Association of body mass index (BMI) with critical COVID-19  
656 and in-hospital mortality: A dose-response meta-analysis. *Metabolism.* 2021;117:154373.

657 150. Chu Y, Yang J, Shi J, Zhang P, Wang X. Obesity is associated with increased severity of disease in  
658 COVID-19 pneumonia: a systematic review and meta-analysis. *Eur J Med Res.* 2020;25(1):64.

659 151. Khaodhiar L, McCowen KC, Blackburn GL. Obesity and its comorbid conditions. *Clin Cornerstone.*  
660 1999;2(3):17-31.

661 152. Dube S, Norby BJ, Pattan V, Carter RE, Basu A, Basu R. 11 $\beta$ -hydroxysteroid dehydrogenase types  
662 1 and 2 activity in subcutaneous adipose tissue in humans: implications in obesity and diabetes.  
663 *J Clin Endocrinol Metab.* 2015;100(1):E70-76.

664 153. Kruglikov IL, Scherer PE. The Role of Adipocytes and Adipocyte-Like Cells in the Severity of  
665 COVID-19 Infections. *Obesity (Silver Spring).* 2020;28(7):1187-1190.

666 154. Tounian P, Aggoun Y, Dubern B, et al. Presence of increased stiffness of the common carotid  
667 artery and endothelial dysfunction in severely obese children: a prospective study. *Lancet.*  
668 2001;358(9291):1400-1404.

669 155. Jin Y, Ji W, Yang H, Chen S, Zhang W, Duan G. Endothelial activation and dysfunction in COVID-  
670 19: from basic mechanisms to potential therapeutic approaches. *Signal Transduction and*  
671 *Targeted Therapy.* 2020;5(1):293.

672 156. Gavriilaki E, Anyfanti P, Gavriilaki M, Lazaridis A, Douma S, Gkaliagkousi E. Endothelial  
673 Dysfunction in COVID-19: Lessons Learned from Coronaviruses. *Curr Hypertens Rep.*  
674 2020;22(9):63.

675 157. Cabandugama PK, Gardner MJ, Sowers JR. The Renin Angiotensin Aldosterone System in Obesity  
676 and Hypertension: Roles in the Cardiorenal Metabolic Syndrome. *Med Clin North Am.*  
677 2017;101(1):129-137.

678 158. Blokhin IO, Lentz SR. Mechanisms of thrombosis in obesity. *Curr Opin Hematol.* 2013;20(5):437-  
679 444.

680 159. Kwaifa IK, Bahari H, Yong YK, Noor SM. Endothelial Dysfunction in Obesity-Induced  
681 Inflammation: Molecular Mechanisms and Clinical Implications. *Biomolecules.* 2020;10(2).

682 160. Prieto D, Contreras C, Sánchez A. Endothelial dysfunction, obesity and insulin resistance. *Curr*  
683 *Vasc Pharmacol.* 2014;12(3):412-426.

684 161. Viridis A. Endothelial Dysfunction in Obesity: Role of Inflammation. *High Blood Press Cardiovasc*  
685 *Prev.* 2016;23(2):83-85.

686 162. Anfossi G, Russo I, Trovati M. Platelet dysfunction in central obesity. *Nutr Metab Cardiovasc Dis.*  
687 2009;19(6):440-449.

688 163. Daryabor G, Kabelitz D, Kalantar K. An update on immune dysregulation in obesity-related  
689 insulin resistance. *Scand J Immunol.* 2019;89(4):e12747.

690 164. Danziger J, Chen KP, Lee J, et al. Obesity, Acute Kidney Injury, and Mortality in Critical Illness.  
691 *Critical care medicine.* 2016;44(2):328-334.

692 165. Akinnusi ME, Pineda LA, El Solh AA. Effect of obesity on intensive care morbidity and mortality: a  
693 meta-analysis. *Crit Care Med.* 2008;36(1):151-158.

694 166. Hogue CW, Jr., Stearns JD, Colantuoni E, et al. The impact of obesity on outcomes after critical  
695 illness: a meta-analysis. *Intensive Care Med.* 2009;35(7):1152-1170.

696 167. Oliveros H, Villamor E. Obesity and mortality in critically ill adults: a systematic review and meta-  
697 analysis. *Obesity (Silver Spring).* 2008;16(3):515-521.

698 168. Zhao Y, Li Z, Yang T, Wang M, Xi X. Is body mass index associated with outcomes of mechanically  
699 ventilated adult patients in intensive critical units? A systematic review and meta-analysis. *PLoS*  
700 *One.* 2018;13(6):e0198669.

701 169. Motaib I, Zbiri S, Elamari S, Dini N, Chadli A, El Kettani C. Obesity and Disease Severity Among  
702 Patients With COVID-19. *Cureus Journal of Medical Science.* 2021;13(2):e13165.

703 170. National Heart L, and Blood Institute,. Development and Use of Study Quality Assessment Tools.  
704 <https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools>. Updated 04/14/2021.  
705 Accessed 04/14/2021, 2020.

706

707

708 **Legends:**

709 **Figure 1:** Prisma flow diagram

710 **Figure 2:** Forest plot for severity analysis

711 **Figure 3:** Forest plot for mortality analysis

712 **Figure 4:** Severity meta-regression analysis

713 **Figure 5:** Mortality meta-regression analysis


714 **Figure 6: 6A:** Sensitivity analysis for mortality for BMI 18 kg/m<sup>2</sup>-25 kg/m<sup>2</sup> vs BMI 30 kg/m<sup>2</sup>-40  
715 kg/m<sup>2</sup>, **6B:** Sensitivity analysis for mortality for BMI 18 kg/m<sup>2</sup>-25 kg/m<sup>2</sup> vs BMI >40 kg/m<sup>2</sup>, **6C:**  
716 Sensitivity analysis for mortality for BMI <18 kg/m<sup>2</sup> vs BMI 18 kg/m<sup>2</sup>-25 kg/m<sup>2</sup>, **6D:** Sensitivity  
717 analysis for mortality for BMI 18 kg/m<sup>2</sup>-24.9 kg/m<sup>2</sup> vs BMI 25 kg/m<sup>2</sup>-29.9 kg/m<sup>2</sup>, **6E:**  
718 Sensitivity analysis for severity of COVID-19 BMI <18 kg/m<sup>2</sup> vs BMI 18 kg/m<sup>2</sup> -25 kg/m<sup>2</sup>, **6F:**  
719 Sensitivity analysis for severity of COVID-19 BMI 18 kg/m<sup>2</sup> -25 kg/m<sup>2</sup> vs BMI 30 kg/m<sup>2</sup> – 40  
720 kg/m<sup>2</sup>, **6G:** Sensitivity analysis for severity of COVID-19 BMI 18 kg/m<sup>2</sup> -25 kg/m<sup>2</sup> vs BMI >40  
721 kg/m<sup>2</sup>, **6H:** Sensitivity analysis for severity of COVID-19 BMI 18 kg/m<sup>2</sup> -25 kg/m<sup>2</sup> vs BMI 25  
722 kg/m<sup>2</sup>-29.9 kg/m<sup>2</sup>.

723 **Figure 7. 7A:** Standard error plot for severity analysis, **7B:** Standard error plot for mortality  
724 analysis.

725 **Figure 8:** Several mechanisms of obesity’s role in endothelial dysfunction: A central event in  
726 pathogenicity of COVID-19 infection

727 **Table 1:** Study characteristics

728 **Table 2:** Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies, **2a:**  
729 Cohort studies, **2b:** Case control studies




730

731

732 **Figure 1:** Prisma flow diagram

733


734



735

736 **Figure 2:** Forest plot for severity analysis.


737




738 **Figure 3:** Forest plot for mortality analysis.

739


Regression of Log odds ratio on Female




Regression of Log odds ratio on Cardiovascular disease




Regression of Log odds ratio on Pulmonary Disease



Regression of Log odds ratio on Age



Regression of Log odds ratio on Diabetes



Regression of Log odds ratio on HTN






Figure 4: Severity meta-regression analysis




Regression of Log odds ratio on Gender




Regression of Log odds ratio on Pulmonary disease



Regression of Log odds ratio on Cardiovascular disease



Regression of Log odds ratio on Hypertension



Regression of Log odds ratio on Diabetes







Figure 5: Mortality meta-regression analysis




**Figure 6A:** Sensitivity analysis for mortality for BMI 18 kg/m<sup>2</sup>-25 kg/m<sup>2</sup> vs BMI 30 kg/m<sup>2</sup>-40 kg/m<sup>2</sup>




**Figure 6B:** Sensitivity analysis for mortality for BMI 18 kg/m<sup>2</sup>-25 kg/m<sup>2</sup> vs BMI >40 kg/m<sup>2</sup>




**Figure 6C:** Sensitivity analysis for mortality for BMI <18 kg/m<sup>2</sup> vs BMI 18 kg/m<sup>2</sup>-25 kg/m<sup>2</sup>




**Figure 6D:** Sensitivity analysis for mortality for BMI 18 kg/m<sup>2</sup>-24.9 kg/m<sup>2</sup> vs BMI 25 kg/m<sup>2</sup>-29.9 kg/m<sup>2</sup>




**Figure 6E:** Sensitivity analysis for severity of COVID-19 BMI <18 kg/m<sup>2</sup> vs BMI 18 kg/m<sup>2</sup>-25 kg/m<sup>2</sup>




**Figure 6F:** Sensitivity analysis for severity of COVID-19 BMI 18 kg/m<sup>2</sup>-25 kg/m<sup>2</sup> vs BMI 30 kg/m<sup>2</sup>-40 kg/m<sup>2</sup>




**Figure 6G:** Sensitivity analysis for severity of COVID-19 BMI 18 kg/m<sup>2</sup>-25 kg/m<sup>2</sup> vs BMI >40 kg/m<sup>2</sup>




**Figure 6H:** Sensitivity analysis for severity of COVID-19 BMI 18 kg/m<sup>2</sup>-25 kg/m<sup>2</sup> vs BMI 25 kg/m<sup>2</sup>-29.9 kg/m<sup>2</sup>



**Figure 7A:** Standard error plot for severity analysis.



**Figure 7B:** Standard error plot for mortality analysis.



**Figure 8:** Several mechanisms of obesity’s role in endothelial dysfunction: A central event in pathogenicity of COVID-19 infection

**Table 1:** Study characteristics

Study	Study Design	Definition of Severity	Total COVID-19 Positive Patients	Total Patients with Obesity	Median Age	Female Sex Proportion	Diabetes Proportion	Heart Disease Proportion	Pulmonary Disease Proportion	Hypertension Proportion
<i>Al Heialy et al.</i> <sup>42</sup>	Cohort	ICU admissions	286	102	46.9	27.2	26.2	3.8	3.8	25.8
<i>Al-Sabah et al.</i> <sup>43</sup>	Cohort	ICU admissions	1158	157	40.5	18.4	23.4	N/A	N/A	20.4
<i>Alkhatib et al.</i> <sup>44</sup>	Retrospective cohort	ICU admissions	158	96	57	61.4	48.1	13.3	17.5	67.7
<i>Anderson et al.</i> <sup>45</sup>	Retrospective cohort	Intubation	2466	785	67	42	40	7	17	52
<i>Andrea Rossi et al.</i> <sup>116</sup>	Cohort	Not valid	95	35	N/A	18	19	38.9	N/A	47.4
<i>Argenziano et al.</i> <sup>107</sup>	Cohort	ICU admission	1000	352	63	40.4	37.2	23.3	22.3	60.1
<i>Arjun S et al.</i> <sup>46</sup>	Cohort	ICU admissions	142	54	N/A	N/A	N/A	N/A	N/A	N/A
<i>Bellan et al.</i> <sup>115</sup>	Cohort	Not valid	407	60	71	41	24	30	3	58
<i>Bhatraju et al.</i> <sup>47</sup>	Cohort	ICU admissions	24	13	64	38	58	N/A	16	N/A
<i>Biscarin et al.</i> <sup>48</sup>	Retrospective cohort	ICU admissions	427	80	67	31.8	19	28	N/A	50
<i>Borobia et al.</i> <sup>140</sup>	Cohort	Not valid	2226	242	61	51.8	17.1	19.3	13.3	41.3
<i>Burrell et al.</i> <sup>49</sup>	Cohort	Mechanical ventilation	204	80	63.5	31	28	20	11	24
<i>Busetto et al.</i> <sup>50</sup>	Cohort	ICU admission	92	29	70.5	39.1	30.4	31.5	13	64.1
<i>Cai et al.</i> <sup>51</sup>	Cohort	ICU admission	383	41	48	52.2	7.3	4.9	N/A	15.1
<i>Cariou et al.</i> <sup>52</sup>	Cohort	Mechanical ventilation	1117	428	69.8	35.1	88.5	11.6	10.4	77.2
<i>Carrillo-Vega et al.</i> <sup>117</sup>	Cohort	Not valid	3922	987	54.2	35	30	5.1	8.1	34.1
<i>Castelnuova et al.</i> <sup>133</sup>	Cohort	Not valid	3894	376	67	38.3	19	21.1	14.3	49.4
<i>caussy et al.</i> <sup>53</sup>	Cohort	Mechanical ventilation	291	96	N/A	N/A	N/A	N/A	N/A	N/A
<i>Cedano et al.</i> <sup>118</sup>	Cohort	Not valid	132	59	63	41	45	24	13	59
<i>Chand et al.</i> <sup>111</sup>	Cohort	Not valid	300	163	58.2	39.3	44.7	13.7	18.7	66.7
<i>Chao et al.</i> <sup>54</sup>	Cohort	ICU admissions	46	12	13.1	32.7	N/A	2.1	24	N/A
<i>Ciceri et al.</i> <sup>112</sup>	Prospective case control	Not valid	410	78	65	27.1	17.8	12.4	5.3	49.5
<i>Claudia et al.</i> <sup>99</sup>	Cohort	ICU admissions	99	27	67	37	22	28	21	57

**Table 1:** Study characteristics (continued)

<b>Cravedi <i>et al.</i><sup>113</sup></b>	Cohort	Not valid	144	71	62	34.02	52	28	18.8	95
<b>Czernichow <i>et al.</i><sup>55</sup></b>	Cohort	ICU admissions	5,795	1264	58	34.5	42.6	4.5	N/A	53.4
<b>de Andrade <i>et al.</i><sup>114</sup></b>	Cohort	Not valid	89405	655	58.9	43.5	1.5	N/A	N/A	4.2
<b>Docherty <i>et al.</i><sup>119</sup></b>	Cohort	Not valid	20133	1685	72.9	40.1	20.7	30.9	16.11	N/A
<b>Dreher <i>et al.</i><sup>56</sup></b>	Cohort	ARDS	50	17	65	34	58	N/A	50	70
<b>Ebinger <i>et al.</i><sup>57</sup></b>	Cohort	ICU admissions	214	44	62	37	40	21	20	54.6
<b>Fava <i>et al.</i><sup>134</sup></b>	Cohort	Not valid	104	28	59.7	42.3	30.8	29.8	15.4	86.5
<b>Feuth <i>et al.</i><sup>58</sup></b>	Cohort	ICU admissions	28	10	56	46	25	N/A	21	43
<b>Fusco <i>et al.</i><sup>100</sup></b>	Cohort	ICU admission + Mechanical ventilation	173942	46965	63	48.9	40.7	73.5	22.2	64.8
<b>Gao <i>et al.</i><sup>59</sup></b>	Cohort	Not mentioned	150	75	48	37.8	19.3	N/A	N/A	N/A
<b>Genny Carrillo <i>et al.</i><sup>101</sup></b>	Retrospective cohort	Mechanical ventilation	69334	16272	55.29	37.38	30.92	4.21	5.65	34.41
<b>Gerotziapas <i>et al.</i><sup>60</sup></b>	Cohort	ICU admissions	430	67	64.3	61	21.6	N/A	9	47.7
<b>Giacomelli <i>et al.</i><sup>121</sup></b>	Cohort	Not valid	233	38	61	30.9	N/A	N/A	N/A	N/A
<b>Giorgi Rossi <i>et al.</i><sup>122</sup></b>	Cohort	Not valid	1075	34	63.2	38.8	17	31	8.4	26
<b>Goyal <i>et al.</i><sup>61</sup></b>	Cohort	Mechanical ventilation	393	136	62.2	39.4	25.2	13.7	17.6	50.1
<b>Guner <i>et al.</i><sup>62</sup></b>	Cohort	ARDS, sepsis, and septic shock	222	77	50.6	40.5	13.5	23.6	5.4	23.4
<b>Hajifathalian <i>et al.</i><sup>63</sup></b>	Cohort	ICU admissions	770	277	64	39.2	31	21	17.4	56.1
<b>Halasz <i>et al.</i><sup>123</sup></b>	Cohort	Not valid	242	48	64	18.2	15.3	14.5	8.7	45.5
<b>Halvatsiotis <i>et al.</i><sup>139</sup></b>	Cohort	Not valid	90	31	65.5	20	18.8	21.1	12	50
<b>Hojo de Souza <i>et al.</i><sup>120</sup></b>	Retrospective cohort	Not valid	44128	3633	N/A	45.85	39.82	52.02	6.31	N/A
<b>Hsu <i>et al.</i><sup>108</sup></b>	Cohort	ICU admissions	1088	565	63	45	35.7	19.7	24.3	57
<b>Hur <i>et al.</i><sup>64</sup></b>	Cohort	Intubation	486	259	59	44.2	32.9	22.8	16	54.9
<b>Ioannou <i>et al.</i><sup>66</sup></b>	Cohort	Mechanical ventilation	3465	1412	61.1	19.6	48.8	47.3	33	75
<b>John Xie <i>et al.</i><sup>106</sup></b>	Retrospective cohort	ICU admissions	287	187	61.5	56.8	53.6	14.3	20.5	80.1
<b>Kaeuffer <i>et al.</i><sup>67</sup></b>	Cohort	Death or admission to ICU	1045	351	66.3	41.4	25.3	11.6	16.5	52.4
<b>Kalligeros <i>et al.</i><sup>32</sup></b>	Cohort	ICU admissions	103	49	60	39.8	36.8	24.2	19.5	64
<b>Kates <i>et al.</i><sup>124</sup></b>	Cohort	Not valid	482	166	57.5	28.8	51	30.1	10.4	77.4
<b>Klang <i>et al.</i></b>	Cohort	Not valid	3406	1231	N/A	N/A	N/A	N/A	N/A	N/A
<b>Laccarino <i>et al.</i><sup>65</sup></b>	Cohort	ICU admissions	2378	157	68.2	37.4	18.2	26.4	8.5	58.5



**Table 1: Study characteristics (continued)**

<b>Lighter <i>et al.</i><sup>68</sup></b>	Cohort	ICU admissions	3615	1370	N/A	N/A	N/A	N/A	N/A	N/A
<b>Ling Hu <i>et al.</i><sup>102</sup></b>	Cohort	Not mentioned	323	13	61	48.6	14.6	12.7	10.9	32.5
<b>Lodigiani <i>et al.</i><sup>69</sup></b>	Cohort	ICU admissions	361	87	66	32	22.7	N/A	N/A	47.2
<b>Marcello <i>et al.</i><sup>135</sup></b>	Cohort	Not valid	6248	2278	61	38	33	31	11	37
<b>Mejía-Vilet.<sup>70</sup></b>	Cohort	ICU admissions	329	132	49	36	24	N/A	N/A	27
<b>Mendy <i>et al.</i><sup>71</sup></b>	Cohort	Death or admission to ICU	216	53	60	44.4	43.5	77.3	16.7	N/A
<b>Menezes Soares <i>et al.</i><sup>136</sup></b>	Cohort	Not valid	1152	111	N/A	42.8	24	45.6	9.6	N/A
<b>Mikami <i>et al.</i><sup>137</sup></b>	Cohort	Not valid	3708	288	66	43	24.3	N/A	8.7	34.3
<b>Monteiro <i>et al.</i><sup>72</sup></b>	Cohort	Mechanical ventilation	112	40	61	34	64	15	17.4	50
<b>Motaib <i>et al.</i><sup>169</sup></b>	Cohort	ICU admissions	107	24	53	40	15	15	8.4	30.8
<b>Mughal <i>et al.</i><sup>73</sup></b>	Cohort	Mechanical ventilation	129	18	63	37.2	19.4	17.1	10.9	43.3
<b>Murillo-Zamora <i>et al.</i><sup>126</sup></b>	Cohort	Not valid	5393	1197	N/A	36.4	31.1	N/A	7.8	36.6
<b>Nachega <i>et al.</i><sup>74</sup></b>	Cohort	ICU admissions	766	39	46	34.4	14	3.9	3.4	25.4
<b>Nakeshbandi <i>et al.</i><sup>75</sup></b>	Cohort	Mechanical ventilation	504	215	68	48	53	19	16	83
<b>Newton <i>et al.</i><sup>76</sup></b>	Cohort	Death or admission to ICU	370	102	62.2	51.8	42.3	17.4	2.5	66.8
<b>Olivas-Martínez <i>et al.</i><sup>127</sup></b>	Cohort	Not valid	800	357	51.9	39	26	4.6	2.3	30
<b>Ortiz-Brizuela <i>et al.</i><sup>77</sup></b>	Cohort	ICU admissions	140	50	49	29.3	22.9	4.3	2.8	32
<b>Palaiodimos <i>et al.</i><sup>78</sup></b>	Cohort	ICU admissions	200	46	64	51	39.5	33.5	27.5	76
<b>Parker <i>et al.</i><sup>128</sup></b>	Cohort	Not valid	113	32	48	61	39	5.4	17.2	42
<b>Parra-Bracamonte <i>et al.</i><sup>129</sup></b>	Cohort	Not valid	95458	22390	44	38.1	31.3	4.2	5.8	35.1
<b>Peng <i>et al.</i><sup>138</sup></b>	Cohort	Not mentioned	112	33	62	59	N/A	55.3	N/A	82
<b>Pepe <i>et al.</i><sup>79</sup></b>	Cohort	ICU admission	2214	440	49.6	40.2	9.1	8	12.3	26.2
<b>Petersen, A. <i>et al.</i><sup>80</sup></b>	Cohort	ICU admissions	30	19	65.6	12	5	5	3	15
<b>Petrilli <i>et al.</i><sup>81</sup></b>	Cohort	Mechanical ventilation and ICU admission	2741	1081	63	38.8	34.7	34.8	16.5	62
<b>Pettit <i>et al.</i><sup>82</sup></b>	Cohort	ICU admissions	238	146	58.5	52.5	28.6	21.4	26.5	52.9
<b>Philipose <i>et al.</i><sup>83</sup></b>	Cohort	Not mentioned	368	125	72	40.5	35.4	33.6	28.1	50.2
<b>Pongpirul <i>et al.</i><sup>84</sup></b>	Cohort	Not mentioned	193	22	37	41.5	8.3	1	1.6	16.1
<b>Rachel <i>et al.</i><sup>103</sup></b>	Cohort	Mechanical ventilation	305	127	60	42	35	21	18	52

**Table 1: Study characteristics (continued)**

<b>Ramlall <i>et al.</i><sup>85</sup></b>	Cohort	Mechanical ventilation	6393	831	57.1	50.3	14.2	26.6	N/A	31.1
<b>Rao <i>et al.</i><sup>86</sup></b>	Cohort	Not mentioned	240	114	48	53.8	9.6	17.9	1.2	N/A
<b>Reilev <i>et al.</i><sup>87</sup></b>	Cohort	ICU admissions	450	50	81	38	26	45	28	74
<b>Rodriguez <i>et al.</i><sup>130</sup></b>	Cohort	Not valid	43	11	65.5	27.2	18.6	14	9.3	30.2
<b>Rodríguez-Molinero <i>et al.</i><sup>88</sup></b>	Cohort	Need for oxygen therapy via nonrebreather mask or mechanical ventilation	418	74	N/A	57	23.7	24.1	N/A	52
<b>Rottoli <i>et al.</i><sup>89</sup></b>	Cohort	ICU admissions	482	104	66.2	37.3	15.2	21.2	13.1	51.7
<b>Salacup G <i>et al.</i><sup>131</sup></b>	Cohort	Not valid	242	97	66	49.17	49	14.8	19.8	74
<b>Shah <i>et al.</i><sup>132</sup></b>	Cohort	Not valid	522	481	63	58.2	42.3	22.6	22	79.7
<b>Shekhar <i>et al.</i><sup>90</sup></b>	Cohort	ICU admissions	50	20	55.5	54	36	14	16	34
<b>Simmonet <i>et al.</i><sup>152</sup></b>	Cohort	Mechanical ventilation	124	59	60	27	23	N/A	N/A	49
<b>Steinberg <i>et al.</i><sup>92</sup></b>	Cohort	Mechanical ventilation	210	100	N/A	N/A	N/A	N/A	N/A	N/A
<b>Suleyman <i>et al.</i><sup>93</sup></b>	Cohort	ICU admission	355	210	61.4	53.5	43.4	29.1	40.3	72.7
<b>Tonetti <i>et al.</i><sup>94</sup></b>	Cohort	ICU admissions	700	176	69.4	23	21.8	61.8	14.4	N/A
<b>Urra <i>et al.</i><sup>95</sup></b>	Retrospective case control	ICU admissions	172	17	N/A	39.5	22.6	16.27	9.8	50.5
<b>Vaquero-Roncero <i>et al.</i><sup>96</sup></b>	Cohort	ICU admissions	146	46	N/A	N/A	N/A	N/A	N/A	N/A
<b>Wang J <i>et al.</i><sup>104</sup></b>	Cohort	ICU admissions	297	40	44.3	44.7	8.41	2.02	4.04	16.16
<b>Wang Min <i>et al.</i><sup>3</sup></b>	Retrospective cohort	Respiratory failure	541	60	52	45.29	8.69	5.36	N/A	24.77
<b>Wang R <i>et al.</i><sup>97</sup></b>	Cohort	Not mentioned	96	44	N/A	N/A	N/A	N/A	N/A	52.1
<b>Xiang Ong <i>et al.</i><sup>105</sup></b>	Cohort	ICU admissions	91	40	55	44	19.7	9.9	N/A	33
<b>Zheng <i>et al.</i><sup>98</sup></b>	Cohort	Not mentioned	66	45	47	74.2	24.2	N/A	N/A	28.8

**Table 2: Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies** <sup>170</sup>

**2A: Cohort studies**

Criteria	Al Heialy <i>et al.</i> <sup>42</sup>	Al-Sabah <i>et al.</i> <sup>43</sup>	Alkhatab <i>et al.</i> <sup>44</sup>	Anderson <i>et al.</i> <sup>45</sup>	Andrea Rossi <i>et al.</i> <sup>116</sup>	Argenzi ano <i>et al.</i> <sup>107</sup>	Arjun S <i>et al.</i> <sup>46</sup>	Bellan <i>et al.</i> <sup>115</sup>
Was the research question or objective in this paper clearly stated?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was the study population clearly specified and defined?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was the participation rate of eligible persons at least 50%?	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes
Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was a sample size justification, power description, or variance and effect estimates provided?	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes
For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed?	No	No	No	No	No	No	No	No
For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)?	Yes	Yes	No	Yes	No	No	Yes	NA
Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes
Was the exposure(s) assessed more than once over time?	NA	NA	No	No	No	No	No	No
Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?	Yes	Yes	No	Yes	Yes	NA	NA	NA
Were the outcome assessors blinded to the exposure status of participants?	CD	CD	CD	CD	CD	Yes	NA	Yes
Was loss to follow-up after baseline 20% or less?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)?	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes
<b>Quality Rating (Good, Fair, or Poor)</b>	Good	Good	Low	Good	Good	Good	Low	Good
<b>Risk of Bias</b>	Low	Low	Moderate	Low	Low	Low	Moderate	Low

CD, cannot determine; NA, not applicable; NR, not reported

## 2A: Cohort studies (continued)

Criteria	Bhatraj u et al. <sup>47</sup>	Biscari n et al. <sup>48</sup>	Borobi a et al. <sup>140</sup>	Burrell et al. <sup>49</sup>	Busett o et al. <sup>50</sup>	Cai et al. <sup>51</sup>	Cariou et al. <sup>52</sup>	Cravedi et al. <sup>113</sup>
Was the research question or objective in this paper clearly stated?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was the study population clearly specified and defined?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was the participation rate of eligible persons at least 50%?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was a sample size justification, power description, or variance and effect estimates provided?	No	Yes	Yes	Yes	No	Yes	Yes	Yes
For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured?	No	Yes	Yes	Yes	No	Yes	Yes	Yes
Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed?	NA	No	NO	No	No	No	NA	No
For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)?	NA	Yes	Yes	No	Yes	NA	CD	Yes
Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was the exposure(s) assessed more than once over time?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No
Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?	NA	NA	Na	NA	Yes	NA	Yes	Yes
Were the outcome assessors blinded to the exposure status of participants?	NA	Yes	Yes	Yes	NA	NA	CD	CD
Was loss to follow-up after baseline 20% or less?	Yes	Yes	Yes	Yes	NA	Yes	Yes	Yes
Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)?	CD	Yes	Yes	No	Yes	Yes	Yes	Yes
<b>Quality Rating (Good, Fair, or Poor)</b>	Low	High	High	Good	Low	Good	Good	Good
<b>Risk of Bias</b>	Moderate	Very low	Very low	Low	Moderate	Low	Low	Low

CD, cannot determine; NA, not applicable; NR, not reported

## 2A: Cohort studies (continued)

Criteria	Carrillo-Vega <i>et al.</i> <sup>117</sup>	Castelnuova <i>et al.</i> <sup>133</sup>	Caussy <i>et al.</i> <sup>53</sup>	Cedano <i>et al.</i> <sup>118</sup>	Chand <i>et al.</i> <sup>111</sup>	Chao <i>et al.</i> <sup>54</sup>	Claudia <i>et al.</i> <sup>99</sup>	Czernichow <i>et al.</i> <sup>55</sup>
Was the research question or objective in this paper clearly stated?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was the study population clearly specified and defined?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was the participation rate of eligible persons at least 50%?	Yes	Yes	yes	Yes	Yes	Yes	Yes	Yes
Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was a sample size justification, power description, or variance and effect estimates provided?	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes
For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured?	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes
Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed?	No	NO	NA	No	No	No	NO	No
For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)?	No	Yes	CD	Yes	Yes	Yes	Yes	CD
Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was the exposure(s) assessed more than once over time?	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?	Yes	Yes	CD	Yes	NA	Yes	Na	NA
Were the outcome assessors blinded to the exposure status of participants?	CD	CD	CD	CD	NA	CD	Yes	CD
Was loss to follow-up after baseline 20% or less?	Yes	NA	Yes	NA	Yes	Yes	Yes	Yes
Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
<b>Quality Rating (Good, Fair, or Poor)</b>	Good	Good	Low	Good	Good	High	High	Good
<b>Risk of Bias</b>	Low	Low	Moderate	Low	Low	Very low	Very low	Low

CD, cannot determine; NA, not applicable; NR, not reported

## 2A: Cohort studies (continued)

Criteria	de Andrade <i>et al.</i> <sup>114</sup>	Docherty <i>et al.</i> <sup>119</sup>	Dreher <i>et al.</i> <sup>56</sup>	Ebinger <i>et al.</i> <sup>57</sup>	Fava <i>et al.</i> <sup>134</sup>	Feuth <i>et al.</i> <sup>58</sup>	Fusco <i>et al.</i> <sup>100</sup>	Gao <i>et al.</i> <sup>59</sup>
Was the research question or objective in this paper clearly stated?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was the study population clearly specified and defined?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was the participation rate of eligible persons at least 50%?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was a sample size justification, power description, or variance and effect estimates provided?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured?	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed?	No	No	No	No	No	No	No	NO
For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)?	No	Yes	Yes	No	No	Yes	Yes	Yes
Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?	Yes	Yes	No	Yes	No	No	No	No
Was the exposure(s) assessed more than once over time?	Yes	Yes	Yes	Yes	Yes	Yes	No	No
Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Were the outcome assessors blinded to the exposure status of participants?	NR	Yes	CD	CD	Yes	CD	Yes	CD
Was loss to follow-up after baseline 20% or less?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
<b>Quality Rating (Good, Fair, or Poor)</b>	Good	High	Good	Good	Good	Good	Good	Good
<b>Risk of Bias</b>	Low	Very low	Low	Low	Low	Low	Low	Low

CD, cannot determine; NA, not applicable; NR, not reported

## 2A: Cohort studies (continued)

Criteria	Genny Carrillo <i>et al.</i> <sup>101</sup>	Gerotziafas <i>et al.</i> <sup>60</sup>	Giacome Ili <i>et al.</i> <sup>121</sup>	Giorgi rossi <i>et al.</i> <sup>122</sup>	Goyal <i>et al.</i> <sup>61</sup>	Guner <i>et al.</i> <sup>62</sup>	Hajifathalian <i>et al.</i> <sup>63</sup>	Halasz <i>et al.</i> <sup>123</sup>
Was the research question or objective in this paper clearly stated?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was the study population clearly specified and defined?	Yes	Yes	yes	Yes	Yes	Yes	Yes	Yes
Was the participation rate of eligible persons at least 50%?	Yes	Yes	yes	Yes	Yes	Yes	Yes	Yes
Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was a sample size justification, power description, or variance and effect estimates provided?	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes
For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured?	Yes	Yes	Yes	Yes	NO	Yes	Yes	Yes
Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed?	No	Yes	Yes	Yes	No	No	No	No
For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)?	Yes	No	No	No	No	Yes	Yes	Yes
Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?	NO	Yes	No	No	Yes	No	Yes	Yes
Was the exposure(s) assessed more than once over time?	No	Yes	Yes	No	No	No	Yes	NO
Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Were the outcome assessors blinded to the exposure status of participants?	CD	CD	No	CD	No	CD	CD	CD
Was loss to follow-up after baseline 20% or less?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)?	No	No	No	Yes	No	Yes	Yes	Yes
<b>Quality Rating (Good, Fair, or Poor)</b>	Fair	Fair	Good	Good	Low	Good	High	Good
<b>Risk of Bias</b>	Unclear	Unclear	Low	Low	Moderate	Low	Very low	Low

CD, cannot determine; NA, not applicable; NR, not reported

## 2A: Cohort studies (continued)

Criteria	Halvatsi otis et al. <sup>139</sup>	Hojo de Souza et al. <sup>120</sup>	Hsu et al. <sup>108</sup>	Hur et al. <sup>64</sup>	Laccarin o et al. <sup>65</sup>	Ioannou et al. <sup>66</sup>	John Xie et al. <sup>106</sup>	Kaeuffer et al. <sup>67</sup>
Was the research question or objective in this paper clearly stated?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was the study population clearly specified and defined?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was the participation rate of eligible persons at least 50%?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was a sample size justification, power description, or variance and effect estimates provided?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured?	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes
Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed?	No	No	No	No	No	No	No	No
For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?	Yes	Yes	No	Yes	Yes	Yes	Yes'	Yes
Was the exposure(s) assessed more than once over time?	No	No	Yes	No	No	Yes	Yes	Yes
Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Were the outcome assessors blinded to the exposure status of participants?	CD	CD	CD	CD	Yes	No	Yes	Yes
Was loss to follow-up after baseline 20% or less?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)?	Yes	Yes	No	Yes	NA	Yes	CD	Yes
<b>Quality Rating (Good, Fair, or Poor)</b>	Good	Good	Good	Good	Good	High	High	High
<b>Risk of Bias</b>	Low	Low	Low	Low	Low	Very low	Very low	Very low

CD, cannot determine; NA, not applicable; NR, not reported



## 2A: Cohort studies (continued)

Criteria	Kalligeros <i>et al.</i> <sup>32</sup>	Kates <i>et al.</i> <sup>124</sup>	Klang <i>et al.</i> <sup>125</sup>	Lighter <i>et al.</i> <sup>68</sup>	Ling Hu <i>et al.</i> <sup>102</sup>	Lodigiani <i>et al.</i> <sup>69</sup>	Marcello <i>et al.</i> <sup>135</sup>	Mejía-Vilet <i>et al.</i> <sup>70</sup>
Was the research question or objective in this paper clearly stated?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was the study population clearly specified and defined?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was the participation rate of eligible persons at least 50%?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was a sample size justification, power description, or variance and effect estimates provided?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed?	No	No	No	No	CD	CD	No	No
For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?	Yes	Yes	No	No	Yes	Yes	Yes	Yes
Was the exposure(s) assessed more than once over time?	Yes	No	Yes	No	No	Yes	No	Yes
Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Were the outcome assessors blinded to the exposure status of participants?	CD	CD	CD	CD	Yes	Yes	No	No
Was loss to follow-up after baseline 20% or less?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)?	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes
<b>Quality Rating</b>	High	Good	Good	Fair	High	Good	Good	High
<b>Risk of Bias</b>	Very low	Low	Low	Unclear	Very low	Low	Low	Very low

CD, cannot determine; NA, not applicable; NR, not reported

## 2A: Cohort studies (continued)

Criteria	Mendy <i>et al.</i> <sup>71</sup>	Menezes Soares <i>et al.</i> <sup>136</sup>	Mikami <i>et al.</i> <sup>137</sup>	Monteiro <i>et al.</i> <sup>72</sup>	Motaib <i>et al.</i> <sup>169</sup>	Mughal <i>et al.</i> <sup>73</sup>	Murillo- Zamora <i>et al.</i> <sup>126</sup>	Nachega <i>et al.</i> <sup>74</sup>
Was the research question or objective in this paper clearly stated?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was the study population clearly specified and defined?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was the participation rate of eligible persons at least 50%?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was a sample size justification, power description, or variance and effect estimates provided?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed?	Yes	No	No	No	No	Yes	No	No
For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was the exposure(s) assessed more than once over time?	No	Yes	Yes	Yes	No	Yes	Yes	No
Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Were the outcome assessors blinded to the exposure status of participants?	CD	CD	CD	CD	No	CD	CD	CD
Was loss to follow-up after baseline 20% or less?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
<b>Quality Rating</b>	High	High	Good	High	Good	High	High	Good
<b>Risk of Bias</b>	Very low	Very low	Low	Very low	Low	Very low	Very low	Low

CD, cannot determine; NA, not applicable; NR, not reported

## 2A: Cohort studies (continued)

Criteria	Nakeshbandi <i>et al.</i> <sup>75</sup>	Newton <i>et al.</i> <sup>76</sup>	Olivas-Martínez <i>et al.</i> <sup>127</sup>	Ortiz-Brizuela <i>et al.</i> <sup>77</sup>	Palaiodimos <i>et al.</i> <sup>78</sup>	Parker <i>et al.</i> <sup>128</sup>	Parra-Bracamonte <i>et al.</i> <sup>129</sup>	Peng <i>et al.</i> <sup>138</sup>
Was the research question or objective in this paper clearly stated?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was the study population clearly specified and defined?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was the participation rate of eligible persons at least 50%?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was a sample size justification, power description, or variance and effect estimates provided?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured?	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes
Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed?	No	No	No	No	No	No	No	No
For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes
Was the exposure(s) assessed more than once over time?	No	Yes	Yes	Yes	CD	CD	No	No
Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Were the outcome assessors blinded to the exposure status of participants?	CD	Yes	Yes	CD	Yes	CD	CD	CD
Was loss to follow-up after baseline 20% or less?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)?	Yes	Yes	Yes	CD	Yes	CD	Yes	Yes
<b>Quality Rating</b>	Good	High	High	Good	High	Good	Good	Good
<b>Risk of Bias</b>	Low	Very low	Very low	Low	Very low	Low	Low	Low

CD, cannot determine; NA, not applicable; NR, not reported

## 2A: Cohort studies (continued)

Criteria	Pepe <i>et al.</i> <sup>79</sup>	Petersen <i>et al.</i> <sup>80</sup>	Petrilli <i>et al.</i> <sup>81</sup>	Pettit <i>et al.</i> <sup>82</sup>	Philipos <i>e et al.</i> <sup>83</sup>	Pongpiru <i>l et al.</i> <sup>84</sup>	Rachel <i>et al.</i> <sup>103</sup>	Ramlall <i>et al.</i> <sup>85</sup>
Was the research question or objective in this paper clearly stated?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was the study population clearly specified and defined?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was the participation rate of eligible persons at least 50%?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was a sample size justification, power description, or variance and effect estimates provided?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed?	No	No	No	No	No	Yes	CD	No
For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was the exposure(s) assessed more than once over time?	No	Yes	No	No	No	Yes	Yes	NO
Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Were the outcome assessors blinded to the exposure status of participants?	CD	CD	NR	CD	CD	Yes	CD	CD
Was loss to follow-up after baseline 20% or less?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)?	Yes	Yes	Yes	CD	Yes	Yes	Yes	Yes
<b>Quality Rating</b>	Good	High	Good	Good	Good	High	High	Good
<b>Risk of Bias</b>	Low	Very low	Low	Low	Low	Very low	Very low	Low

CD, cannot determine; NA, not applicable; NR, not reported

## 2A: Cohort studies (continued)

Criteria	Rao <i>et al.</i> <sup>86</sup>	Reilev <i>et al.</i> <sup>87</sup>	Rodriguez <i>et al.</i> <sup>130</sup>	Rodríguez-Molinero <i>et al.</i> <sup>88</sup>	Salacup <i>G et al.</i> <sup>131</sup>	Rottoli <i>et al.</i> <sup>89</sup>	Shah <i>et al.</i> <sup>132</sup>	Shekhar <i>et al.</i> <sup>90</sup>	Simmonet <i>et al.</i> <sup>152</sup>
Was the research question or objective in this paper clearly stated?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was the study population clearly specified and defined?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was the participation rate of eligible persons at least 50%?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was a sample size justification, power description, or variance and effect estimates provided?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured?	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes
Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed?	CD	No	CD	No	Yes	No	No	No	No
For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes
Was the exposure(s) assessed more than once over time?	No	Yes	No	No	No	No	No	No	No
Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Were the outcome assessors blinded to the exposure status of participants?	Yes	CD	CD	CD	CD	CD	No	CD	Yes
Was loss to follow-up after baseline 20% or less?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
<b>Quality Rating</b>	High	Good	High	Good	Good	Good	High	Good	High
<b>Risk of Bias</b>	Very low	Low	Very low	Low	Low	Low	Very low	Low	Very low

CD, cannot determine; NA, not applicable; NR, not reported

## 2A: Cohort studies (continued)

Criteria	Steinberg <i>et al.</i> <sup>92</sup>	Suleyman <i>et al.</i> <sup>93</sup>	Tonetti <i>et al.</i> <sup>94</sup>	Vaquero-Roncer <i>o et al.</i> <sup>96</sup>	Wang J <i>et al.</i> <sup>104</sup>	Wang Min <i>et al.</i> <sup>3</sup>	Wang R <i>et al.</i> <sup>97</sup>	Xiang <i>et al.</i> <sup>105</sup>	Zheng <i>et al.</i> <sup>98</sup>
Was the research question or objective in this paper clearly stated?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was the study population clearly specified and defined?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was the participation rate of eligible persons at least 50%?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was a sample size justification, power description, or variance and effect estimates provided?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured?	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed?	NO	No	No	No	No	NO	No	No	No
For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)?	Yes	Yes	Yes	Yes	Yes	Yes	yes	Yes	Yes
Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was the exposure(s) assessed more than once over time?	No	No	No	No	NO	No	No	No	No
Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes
Were the outcome assessors blinded to the exposure status of participants?	CD	CD	CD	Yes	CD	CD	CD	CD	CD
Was loss to follow-up after baseline 20% or less?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)?	No	Yes	Yes	Yes	Yes	CD	CD	CD	Yes
<b>Quality Rating</b>	Good	Good	Good	High	Good	Good	Good	Good	Good
<b>Risk of Bias</b>	Low	Low	Low	Very low	Low	Low	Low	Low	Low

## 2B: Case control studies

Criteria	Ciceri <i>et al.</i> <sup>112</sup>	Urra <i>et al.</i> <sup>95</sup>
Was the research question or objective in this paper clearly stated and appropriate?	Yes	Yes
Was the study population clearly specified and defined?	Yes	Yes
Did the authors include a sample size justification?	Yes	Yes
Were controls selected or recruited from the same or similar population that gave rise to the cases (including the same timeframe)?	Yes	Yes
Were the definitions, inclusion and exclusion criteria, algorithms or processes used to identify or select cases and controls valid, reliable, and implemented consistently across all study participants?	Yes	Yes
Were the cases clearly defined and differentiated from controls?	Yes	Yes
If less than 100 percent of eligible cases and/or controls were selected for the study, were the cases and/or controls randomly selected from those eligible?	Yes	Yes
Was there use of concurrent controls?	Yes	No
Were the investigators able to confirm that the exposure/risk occurred prior to the development of the condition or event that defined a participant as a case?	Yes	Yes
Were the measures of exposure/risk clearly defined, valid, reliable, and implemented consistently (including the same time period) across all study participants?	Yes	Yes
Were the assessors of exposure/risk blinded to the case or control status of participants?	NR	NR
Were key potential confounding variables measured and adjusted statistically in the analyses? If matching was used, did the investigators account for matching during study analysis?	Yes	Yes
<b>Quality Rating</b>	High	High
<b>Risk of Bias</b>	Very low	Very low

CD, cannot determine; NA, not applicable; NR, not reported